###begin article-title 0
###xml 66 76 66 76 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Viperidae </italic>
###xml 104 106 104 106 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 22 27 <span type="species:ncbi:9606">human</span>
Characterization of a human coagulation factor Xa-binding site on Viperidae snake venom phospholipases A2 by affinity binding studies and molecular bioinformatics
###end article-title 0
###begin p 1
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
###xml 51 53 51 53 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 59 60 59 60 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 78 88 78 88 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Viperidae </italic>
###xml 397 398 397 398 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 469 474 <span type="species:ncbi:9606">human</span>
The snake venom group IIA secreted phospholipases A2 (SVPLA2), present in the Viperidae snake family exhibit a wide range of toxic and pharmacological effects. They exert their different functions by catalyzing the hydrolysis of phospholipids (PL) at the membrane/water interface and by highly specific direct binding to: (i) presynaptic membrane-bound or intracellular receptors; (ii) natural PLA2-inhibitors from snake serum; and (iii) coagulation factors present in human blood.
###end p 3
###begin title 4
Results
###end title 4
###begin p 5
###xml 86 95 86 95 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 177 187 177 187 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Viperidae </italic>
###xml 198 199 198 199 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 366 367 366 367 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 258 263 <span type="species:ncbi:9606">human</span>
Using surface plasmon resonance (SPR) protein-protein interaction measurements and an in vitro biological test of inhibition of prothrombinase activity, we identify a number of Viperidae venom SVPLA2s that inhibit blood coagulation through direct binding to human blood coagulation factor Xa (FXa) via a non-catalytic, PL-independent mechanism. We classify the SVPLA2s in four groups, depending on the strength of their binding.
###end p 5
###begin p 6
###xml 211 213 211 213 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 305 306 305 306 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 380 383 380 383 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+ </sup>
###xml 463 465 460 462 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
Molecular electrostatic potentials calculated at the surface of 3D homology-modeling models show a correlation with inhibition of prothrombinase activity. In addition, molecular docking simulations between SVPLA2 and FXa guided by the experimental data identify the potential FXa binding site on the SVPLA2s. This site is composed of the following regions: helices A and B, the Ca2+ loop, the helix C-beta-wing loop, and the C-terminal fragment. Some of the SVPLA2 binding site residues belong also to the interfacial binding site (IBS). The interface in FXa involves both, the light and heavy chains.
###end p 6
###begin title 7
Conclusion
###end title 7
###begin p 8
###xml 66 67 66 67 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 266 267 266 267 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
We have experimentally identified several strong FXa-binding SVPLA2s that disrupt the function of the coagulation cascade by interacting with FXa by the non-catalytic PL-independent mechanism. By theoretical methods we mapped the interaction sites on both, the SVPLA2s and FXa. Our findings may lead to the design of novel, non-competitive FXa inhibitors.
###end p 8
###begin title 9
Background
###end title 9
###begin p 10
###xml 182 183 182 183 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
Haemostasis (vasoconstriction, platelet plug formation and blood clotting) is a defense mechanism that evolved to prevent the loss of blood after injury to the transporting vessels [1]. The intrinsic and the extrinsic alternate pathways initiate the blood clotting process. One of the common steps in both pathways of coagulation is the activation of coagulation factor X (FX) to factor Xa (FXa).
###end p 10
###begin p 11
###xml 293 294 289 290 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 720 721 716 717 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 989 990 982 983 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 1502 1503 1495 1496 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 1504 1505 1497 1498 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 1549 1552 1542 1545 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+ </sup>
###xml 1742 1743 1735 1736 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 1744 1745 1737 1738 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
FXa circulates in plasma as the light and the heavy chains connected by a single disulfide linkage. The N-terminal region of the light chain (residues 1-39) is the Gla domain, rich in post-translationaly modified gamma-carboxyglutamic acid, which interacts with the phospholipid (PL) membrane[2]. The Gla domain is followed by a short stack of hydrophobic residues (residues 40-45), and two epidermal growth factor-like repeats - the EGF-like 1 domain (residues 46-84) and the EGF-like 2 domain (residues 85-128). The heavy chain of FXa contains the catalytically active serine proteinase domain (254 amino acids, residues 16-269 in chymotrypsinogen numbering system). As a serine proteinase of the chymotrypsin family [3], FXa consists of two subdomains of antiparallel beta-barrel structure each comprising a sheet of six strands and four helices. Residues His57, Asp102, and Ser195 (chymotrypsinogen numbering) form a catalytic triad at the active site cleft between the two subdomains[4]. The fold contains a number of solvent-exposed loops, which determine S1 and subsite preferences in structurally homologous enzymes of the family. To the north of the active site cleft in the canonical view are the 60- and 99-loops; to the west are the 174 - and the 217-225 loops, restricting access to the active site. The autolysis loop 149-151 occupies the southern boundary of the active site cleft. Adjacent to it is the 70-loop. To the east is the 37-loop. Loop 185-188 is associated with S1 preference[5,6]. Upon binding to FVa in the presence of Ca2+ ions on negatively charged membrane PL at the cellular surface, the prothrombinase complex is formed, resulting in the accelerated conversion of FII (prothrombin) to FIIa (thrombin) by FXa [7,8]. Afterwards, thrombin converts fibrinogen into fibrin, consolidating the primary plug.
###end p 11
###begin p 12
###xml 25 27 25 27 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 32 33 32 33 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 143 145 143 145 <italic xmlns:xlink="http://www.w3.org/1999/xlink">sn</italic>
###xml 381 382 381 382 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 434 435 434 435 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 497 499 497 499 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 500 502 500 502 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 563 565 563 565 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 571 572 571 572 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 629 631 629 631 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 632 634 632 634 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 879 886 879 886 <italic xmlns:xlink="http://www.w3.org/1999/xlink">et al. </italic>
###xml 887 889 887 889 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 963 965 963 965 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 508 513 <span type="species:ncbi:9606">human</span>
Secreted phospholipases A2 (sPLA2, EC 3. 1. 1. 4) are water-soluble interfacial enzymes that catalyze the hydrolysis of the 2-acyl groups in 3-sn-phosphoglycerides. The His48/Asp99 pair, the 26-34 calcium-binding loop and the 69-loop of residues 59-74 constitute the catalytic site. The calcium metal is a cofactor and its pocket is composed of Asp49 and the calcium-binding loop [9]. The Interfacial Binding Site (IBS) of several PLA2s has been located and is species- and enzyme class-specific [10-12]. In human non-pancreatic secreted group IIA phospholipase A2 (hsPLA2), the IBS is located in the "front" face of the enzyme [13,14]. It consists of a highly hydrophobic surface (Val3, Ala18, Leu19, Phe24, Phe70 and Tyr119) that surrounds the active site, and of hydrophilic residues (Arg7, Lys10, Glu16, and His6) (PDB code 1BBC; numbering system throughout as in Renetseder et al. [15]). Two other residues (Lys74 and Lys115) lie in the periphery of the IBS[13].
###end p 12
###begin p 13
###xml 44 45 44 45 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 137 139 137 139 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 150 152 150 152 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 153 155 153 155 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 203 205 203 205 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 206 208 206 208 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 254 256 254 256 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 306 307 306 307 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 401 403 401 403 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 453 455 453 455 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 456 458 456 458 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 496 497 496 497 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 618 620 618 620 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 621 623 621 623 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 812 813 812 813 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 816 818 816 818 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 819 821 819 821 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 824 834 824 834 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Viperidae </italic>
###xml 882 883 882 883 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 891 892 891 892 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 936 938 936 938 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 1028 1030 1028 1030 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 1031 1033 1031 1033 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B40">40</xref>
###xml 1036 1046 1036 1046 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Viperidae </italic>
###xml 1051 1052 1051 1052 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 1114 1116 1114 1116 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 1122 1123 1122 1123 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 1165 1167 1165 1167 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B41">41</xref>
###xml 1168 1170 1168 1170 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B42">42</xref>
###xml 1213 1215 1213 1215 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 1363 1365 1363 1365 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B43">43</xref>
###xml 1366 1368 1366 1368 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B47">47</xref>
###xml 1437 1438 1437 1438 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 1478 1480 1478 1480 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 1481 1483 1481 1483 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B43">43</xref>
###xml 1646 1648 1646 1648 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 1683 1685 1683 1685 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 1686 1688 1686 1688 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B48">48</xref>
###xml 1690 1692 1690 1692 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B49">49</xref>
###xml 1774 1776 1774 1776 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 1935 1937 1935 1937 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 1938 1940 1938 1940 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
###xml 1941 1943 1941 1943 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B34">34</xref>
###xml 1944 1946 1944 1946 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
###xml 1947 1949 1947 1949 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B39">39</xref>
###xml 1950 1952 1950 1952 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B50">50</xref>
###xml 1953 1955 1953 1955 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B51">51</xref>
###xml 1991 1992 1991 1992 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 2075 2077 2075 2077 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 2096 2124 2096 2124 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Naja nigricollis (Elapidae) </italic>
###xml 2130 2132 2130 2132 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 2133 2135 2133 2135 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 1095 1100 <span type="species:ncbi:9606">human</span>
###xml 2096 2112 <span type="species:ncbi:8654">Naja nigricollis</span>
In addition to the esterase activities, sPLA2s are also specific ligands that interact with different targets, such as membrane-bound PLA2 receptors [16,17], anionic heparan sulfate proteoglycans (HSPG)[18,19], and with a cytoskeleton protein (vimentin)[20]. On the other hand, the soluble receptors of PLA2s, such as the natural inhibitors in the blood of snakes, the coagulation factors, and the PLA2 binding protein have been also well characterized[21,22]. Hence, it has become clear that PLA2s exert physiological and patho-physiological effects through protein-protein interaction and/or protein-PL interactions[22,23]. These protein-protein mechanisms are sometimes dependent on, and other times independent of their enzymatic activity, playing important roles in determining the specific function of sPLA2s [24-26]. Viperidae snake venoms contain several toxic group IIA PLA2s (SVPLA2), which may act as presynaptic neurotoxins[27] and may interfere with blood coagulation by possessing strong anticoagulant properties [28-40]. Viperidae SVPLA2s have high primary sequence identity with human group IIA PLA2 (hsPLA2; 30-60%) and overall structural homology[41,42]. Almost all anticoagulant snake venom PLA2 are basic proteins and may inhibit coagulation by several mechanisms. A first mechanism involves the hydrolysis and destruction of procoagulant PL [43-47]. CM-I and CM-II, illustrate this mechanism in which the group I PLA2 inhibits the extrinsic tenase complex [22,43], and does not bind to FXa. A second mechanism is based on the competition with clotting proteins for binding to the lipid surface due to the high affinity of PLA2 toward PL the "antagonist effect" [28,48][49]. A third mechanism is a non-enzymatic, PL-independent mechanism in which the PLA2 interacts with FXa, inhibits the prothrombinase complex by preventing formation of the FXa/FVa complex and introduces a lag time in the generation of thrombin[22,32,34,35,39,50,51]. In addition, some snake venom PLA2s show a combination of enzymatic and non-enzymatic mechanisms, like the basic sPLA2 isoform CM-IV from Naja nigricollis (Elapidae) venom[22,29].
###end p 13
###begin p 14
###xml 102 104 102 104 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
###xml 105 107 105 107 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B34">34</xref>
###xml 127 129 127 129 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 130 132 130 132 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B50">50</xref>
###xml 186 188 186 188 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 413 415 413 415 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 416 418 416 418 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B51">51</xref>
The non-enzymatic inhibition mechanism of the prothrombinase complex was first demonstrated for CM-IV[32,34] and then for hsPLA2 [50]. The catalytically inactive His48Gln mutant of hsPLA2 possesses an identical anticoagulant effect and binds to FXa with the same kinetic constant as the wild-type enzyme, showing that in this mechanism the anticoagulant process is independent of the catalytic activity of the PLA2 [51].
###end p 14
###begin p 15
###xml 183 184 183 184 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 186 188 186 188 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B33">33</xref>
###xml 320 329 317 326 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Elapidae </italic>
###xml 340 341 337 338 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 344 346 341 343 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B52">52</xref>
###xml 347 349 344 346 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B53">53</xref>
###xml 489 491 486 488 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B33">33</xref>
###xml 656 658 653 655 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
Kini and Evans first proposed that a "pharmacological site," in addition to the catalytic site, could explain the specific biological anticoagulant activity of snake venom group I PLA2s[33]. This anticoagulant region consists of the basic exposed loop located in the region 55-70, and the beginning of the beta-sheet on Elapidae group I PLA2s [52,53]. The proposed region is positively charged in strong anticoagulant enzymes, but negatively charged in weak and non-anticoagulant enzymes [33]. More recently, Kini proposed that weakly anticoagulant enzymes, which lack the anticoagulant region, fail to bind specifically to FXa in the coagulation cascade [22].
###end p 15
###begin p 16
###xml 55 65 55 65 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Viperidae </italic>
###xml 70 71 70 71 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 228 229 228 229 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
In spite of all the studies, the corresponding site in Viperidae SVPLA2s is not yet clearly established. In addition, no distinction is usually made between the mechanisms by which the anticoagulant potency is exerted by the PLA2s. It seems that only the mechanisms that imply participation of PL have been taken into account in the past.
###end p 16
###begin p 17
###xml 29 31 29 31 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 233 235 233 235 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B54">54</xref>
###xml 292 294 292 294 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 303 313 303 313 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Viperidae </italic>
###xml 546 548 546 548 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 549 551 549 551 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B51">51</xref>
###xml 644 646 641 643 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B39">39</xref>
###xml 791 801 788 798 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Viperidae </italic>
###xml 806 807 803 804 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 906 907 903 904 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 1181 1183 1178 1180 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
Anticoagulant snake venom PLA2 represent a novel family of agents useful in identifying the sites of interaction of anticoagulants at the level of specific amino acid residues and thus have a potential in identifying new drug leads [54]. In order to characterize the FXa-binding site of SVPLA2 from the Viperidae family, we have focused on the non-enzymatic, PL-independent, anticoagulant mode of action. Previous work from the Unite des Venins (Institut Pasteur, Paris) had shown the involvement of basic residues located around the IBS of hsPLA2 [51], on one hand, and the possible involvement of the C-terminal and beta-wing regions of AtxA[39] in binding to FXa, on the other. We were henceforth interested in determining whether similar or different amino acid patterns were present in Viperidae SVPLA2s. Using SPR and a physiological test of inhibition of prothrombinase activity, we identified SVPLA2s that formed complexes with FXa and determined the apparent affinity constants of the complexes. With this experimental information at hand, we applied sequence analysis, molecular bioinformatics and docking procedures in order to define the anticoagulant region of the PLA2 and the nature of the residues involved in the interaction with FXa.
###end p 17
###begin p 18
###xml 9 10 9 10 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 49 50 49 50 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 146 175 146 175 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Crotalus durissus terrificus </italic>
###xml 226 228 226 228 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B55">55</xref>
###xml 233 234 233 234 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 276 278 276 278 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B56">56</xref>
###xml 339 360 336 357 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pseudocerastes fieldi</italic>
###xml 361 363 358 360 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B57">57</xref>
###xml 411 437 408 434 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Vipera ammodytes ammodytes</italic>
###xml 438 440 435 437 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B58">58</xref>
###xml 457 459 454 456 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 464 482 461 479 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Vipera berus berus</italic>
###xml 483 485 480 482 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B59">59</xref>
###xml 488 491 485 488 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Vbb</italic>
###xml 534 536 531 533 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B60">60</xref>
###xml 543 557 540 554 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Bothrops asper</italic>
###xml 558 560 555 557 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B61">61</xref>
###xml 574 576 571 573 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 581 607 578 604 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Daboia russelli pulchella </italic>
###xml 608 610 605 607 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B62">62</xref>
###xml 639 641 636 638 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 646 671 643 668 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Agkistrodon halys pallas </italic>
###xml 672 674 669 671 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B63">63</xref>
###xml 677 681 674 678 <italic xmlns:xlink="http://www.w3.org/1999/xlink">bAhp</italic>
###xml 705 729 702 726 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Agkistrodon halys pallas</italic>
###xml 730 732 727 729 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B64">64</xref>
###xml 745 747 742 744 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 752 767 749 764 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Crotalus atrox </italic>
###xml 768 770 765 767 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B65">65</xref>
###xml 773 777 770 774 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Catx</italic>
###xml 814 815 811 812 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 816 818 813 815 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B66">66</xref>
###xml 826 827 823 824 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 901 905 898 902 <italic xmlns:xlink="http://www.w3.org/1999/xlink">bAhp</italic>
###xml 913 918 910 915 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Catx </italic>
###xml 927 929 924 926 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 992 993 989 990 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 1015 1018 1012 1015 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Vbb</italic>
###xml 146 174 <span type="species:ncbi:8732">Crotalus durissus terrificus</span>
###xml 339 360 <span type="species:ncbi:47769">Pseudocerastes fieldi</span>
###xml 411 437 <span type="species:ncbi:8705">Vipera ammodytes ammodytes</span>
###xml 464 482 <span type="species:ncbi:31156">Vipera berus berus</span>
###xml 543 557 <span type="species:ncbi:8722">Bothrops asper</span>
###xml 581 606 <span type="species:ncbi:97228">Daboia russelli pulchella</span>
###xml 646 670 <span type="species:ncbi:8714">Agkistrodon halys pallas</span>
###xml 705 729 <span type="species:ncbi:8714">Agkistrodon halys pallas</span>
###xml 752 766 <span type="species:ncbi:8730">Crotalus atrox</span>
###xml 795 800 <span type="species:ncbi:9606">human</span>
The SVPLA2s tested in this study are: CBc and CBa2, two isoforms of the basic subunit of crotoxin (CTX), a non covalent, heterodimeric toxin from Crotalus durissus terrificus formed by the basic CB and the acidic CA subunits [55]; CA2, an isoform of the acidic subunit of CTX[56]; the acidic and basic subunits of the beta-neurotoxin from Pseudocerastes fieldi[57] (CbI and CbII); isoform A of ammodytoxin from Vipera ammodytes ammodytes[58] (AtxA); the PLA2 from Vipera berus berus[59] (Vbb); Myotoxin II (inactive Asp49Lys mutant) [60] from Bothrops asper[61] (MtxII); PLA2 from Daboia russelli pulchella [62] (VRV-PLVIII); the basic PLA2 from Agkistrodon halys pallas [63] (bAhp); agkistrodotoxin from Agkistrodon halys pallas[64] (AGTX); PLA2 from Crotalus atrox [65] (Catx). We also tested human group IIA PLA2[66] (hsPLA2; Uniprot P14555; PDB 1BBC). The crystal structures of MtxII, VRV-PLVIII, bAhp, AGTX, Catx and hsPLA2 are available in the PDB, whereas we structure-modeled CBc, CBa2, CbI, CbII, AtxA and Vbb.
###end p 18
###begin title 19
Results
###end title 19
###begin title 20
###xml 23 24 23 24 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
Identification of SVPLA2s that bind to FXa and inhibit prothrombinase activity
###end title 20
###begin p 21
###xml 18 19 18 19 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 30 31 30 31 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 38 48 38 48 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Viperidae </italic>
###xml 137 138 137 138 <sub xmlns:xlink="http://www.w3.org/1999/xlink">d</sub>
###xml 138 141 138 141 <sup xmlns:xlink="http://www.w3.org/1999/xlink">app</sup>
###xml 234 237 234 237 <sub xmlns:xlink="http://www.w3.org/1999/xlink">50 </sub>
###xml 280 282 280 282 <sub xmlns:xlink="http://www.w3.org/1999/xlink">d </sub>
###xml 282 285 282 285 <sup xmlns:xlink="http://www.w3.org/1999/xlink">app</sup>
###xml 313 315 313 315 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 328 329 328 329 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 449 450 449 450 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 474 477 474 477 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Vbb</italic>
###xml 477 479 477 479 <sub xmlns:xlink="http://www.w3.org/1999/xlink">, </sub>
###xml 495 499 495 499 <italic xmlns:xlink="http://www.w3.org/1999/xlink">bAhp</italic>
###xml 552 553 552 553 <sub xmlns:xlink="http://www.w3.org/1999/xlink">d</sub>
###xml 553 556 553 556 <sup xmlns:xlink="http://www.w3.org/1999/xlink">app</sup>
###xml 582 585 582 585 <sub xmlns:xlink="http://www.w3.org/1999/xlink">50 </sub>
###xml 632 634 632 634 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 639 667 639 667 <italic xmlns:xlink="http://www.w3.org/1999/xlink">A. halys pallas (blomhoffii)</italic>
###xml 736 738 736 738 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B38">38</xref>
###xml 851 856 851 856 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Catx </italic>
###xml 927 928 927 928 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 1081 1083 1081 1083 <sub xmlns:xlink="http://www.w3.org/1999/xlink">d </sub>
###xml 1083 1086 1083 1086 <sup xmlns:xlink="http://www.w3.org/1999/xlink">app</sup>
###xml 1094 1097 1094 1097 <sub xmlns:xlink="http://www.w3.org/1999/xlink">50 </sub>
###xml 1138 1140 1138 1140 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 1202 1203 1202 1203 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 1283 1285 1283 1285 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 1332 1333 1332 1333 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 1459 1460 1459 1460 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 639 647 <span type="species:ncbi:8714">A. halys</span>
As shown in Table 1, the SVPLA2s from Viperidae snake CBc and MtxII interact with FXa with very high affinity and constitute group VS (<Kdapp> 0.6 - 2 nM). These enzymes strongly inhibit the formation of the prothrombinase complex (IC50 1-3 nM). Under identical conditions, the <Kd app> value determined for hsPLA2 is 14 nM. CBa2, AtxA and CbII have high affinity values and anticoagulant potency, and form group S (20-50 nM). A third group of SVPLA2, group M, is formed by Vbb, VRV-PLVIII, and bAhp. In this group, the affinity with FXa is smaller (<Kdapp> 400 - 830 nM) and the IC50 ranges from 90 to 130 nM. AGTX (the neutral PLA2 from A. halys pallas (blomhoffii)), reported previously as weakly anticoagulant in the presence of PL[38], does not interact with FXa and does not inhibit prothrombinase activity in the absence of PL. Neither CbI nor Catx inhibit prothrombinase activity in the absence of PL. These three SVPLA2s constitute group NB. Last, reduced and carboxymethylated CBc does not interact with FXa. Furthermore, we found a positive linear correlation between <Kd app> and IC50 (R = 0.995) for the three groups of SVPLA2 that interact with FXa. Thus, the strongly anticoagulant SVPLA2s bind with high affinity to FXa, whereas the less efficient anticoagulant SVPLA2 possess low affinity for FXa. Also, basic SVPLA2s (8.35<pI<9.10) bound to FXa and inhibited prothrombinase activity, whereas those with acidic pIs (4.60-5.43) did not (Table 1).
###end p 21
###begin p 22
###xml 72 82 72 82 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Viperidae </italic>
###xml 87 88 87 88 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
FXa binding kinetic parameters and effect on prothrombinase activity of Viperidae SVPLA2
###end p 22
###begin p 23
*: estimated
###end p 23
###begin p 24
NB: non-binding
###end p 24
###begin p 25
Nd: not determined
###end p 25
###begin p 26
###xml 2 3 2 3 <sub xmlns:xlink="http://www.w3.org/1999/xlink">d</sub>
###xml 3 6 3 6 <sup xmlns:xlink="http://www.w3.org/1999/xlink">app</sup>
<Kdapp> = <koff>/<kon>
###end p 26
###begin p 27
###xml 6 9 6 9 <sub xmlns:xlink="http://www.w3.org/1999/xlink">50 </sub>
###xml 112 113 112 113 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
The IC50 value corresponds to 50% inhibition of thrombin generation in the absence of PL for the different SVPLA2.
###end p 27
###begin p 28
###xml 57 58 57 58 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 352 354 352 354 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B67">67</xref>
###xml 355 357 355 357 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B68">68</xref>
###xml 422 423 422 423 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 470 473 470 473 <sub xmlns:xlink="http://www.w3.org/1999/xlink">off</sub>
###xml 490 492 490 492 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 617 619 617 619 <sub xmlns:xlink="http://www.w3.org/1999/xlink">d </sub>
###xml 619 622 619 622 <sup xmlns:xlink="http://www.w3.org/1999/xlink">app</sup>
###xml 699 702 699 702 <sub xmlns:xlink="http://www.w3.org/1999/xlink">50 </sub>
###xml 740 742 740 742 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 760 763 760 763 <sub xmlns:xlink="http://www.w3.org/1999/xlink">50 </sub>
###xml 898 900 898 900 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B55">55</xref>
###xml 901 903 901 903 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B68">68</xref>
It is interesting to note that the isoenzymes CBc and CBa2, which differ by 8 amino acids (His1Ser, Ile18Val, Arg34Gln, Pro74Arg, Glu92Lys, Tyr115Asn, Gly116Glu, Gly128Glu) and associate with the acidic subunit CA to form two pharmacologically distinct classes of crotoxin complexes, present differences in toxicity, enzymatic activities and stability[67,68]. These two isoforms bind to FXa with different kinetics (Table 1). The average rate of dissociation constant <koff> for the FXa-CBa2 complex is about two orders of magnitude greater than that of the FXa-CBc complex, implying a more stable FXa-CBc complex (<Kd app> 0.6 nM). Consequently, CBc strongly inhibits the prothrombinase complex (IC50 0.7 nM), whereas the inhibition by CBa2 is much weaker (IC50 41 nM). Indeed, we had observed in the past that the difference in stability between crotoxin isoforms was due only to the CB subunit [55,68].
###end p 28
###begin p 29
###xml 134 136 134 136 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B69">69</xref>
###xml 189 191 189 191 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 240 242 240 242 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B70">70</xref>
###xml 306 308 306 308 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B71">71</xref>
###xml 380 381 380 381 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
###xml 452 453 452 453 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
We also investigated by SPR the possibility of the formation of a ternary CA-CB-FXa complex. On one hand, CA binds to immobilized CB [69], whereas FXa does not interact with immobilized CB[23]. An anti-CA monoclonal antibody (mAb) A-73.13 [70] was covalently attached to the chip, as previously described [71]; CTX was then captured via this mAb before the injection of FXa (Fig. 1). FXa bound to CTX, as seen in the rise of the resonance signal. Fig. 1 also shows that after the injection of a specific anti-CB mAb (B32.13), the signal increased further, indicating the presence of CB on the chip and showing that the CB-FXa complex is stable and remained attached to CA.
###end p 29
###begin p 30
###xml 0 69 0 69 <bold xmlns:xlink="http://www.w3.org/1999/xlink">The interaction between an isoform of CTX and FXa, as measured by SPR</bold>
###xml 173 174 173 174 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
The interaction between an isoform of CTX and FXa, as measured by SPR. The anti-CA monoclonal antibody mAb A-73.13 [70] was covalently attached to the chip [71]. CTX (the CA2-CBc complex) was then captured via this mAb before injection of FXa (25 mug/ml). FXa bound to CTX, as seen in the rise of the resonance signal, showing that the CTX-FXa complex remained attached to the anti-CA mAb. After injection of a specific anti-CB MAb (B-32.13, 10 mug/ml), the signal increased further, confirming the presence of CB in the ternary CA-CB-FXa complex.
###end p 30
###begin title 31
###xml 80 81 80 81 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
Sequence analysis, comparisons and consensus residues of the anticoagulant SVPLA2s
###end title 31
###begin p 32
###xml 97 98 97 98 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 181 182 181 182 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 200 204 200 204 <italic xmlns:xlink="http://www.w3.org/1999/xlink">bAhp</italic>
###xml 206 209 206 209 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Vbb</italic>
###xml 225 229 225 229 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Catx</italic>
In order to identify those residues or sequence patterns that differ between members of the SVPLA2s, we obtained Weblogo plots of the four groups VS (CBc, MtxII), S (CbII, AtxA, CBa2), M (VRV-PLVIII, bAhp, Vbb) and NB (AGTX, Catx, CbI). Thereafter, we performed comparisons of all the sequences among themselves and of the four groups against each other.
###end p 32
###begin p 33
###xml 99 104 99 104 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Catx </italic>
###xml 176 178 176 178 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2A</xref>
###xml 317 319 317 319 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2B</xref>
###xml 462 463 462 463 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 566 568 566 568 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 572 576 572 576 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Vbb </italic>
Considering only segments of three or more residues, we observed three conserved regions for AGTX, Catx and CbI of the NB group (Tyr25-Gly30, Thr41-Gly53 and Cys96-Asp99; Fig. 2A), and six for the CBc-MtxII pair of the VS group (Tyr25-Cys27, Gly33-Gly35, Pro37-Cys45, Cys50-Tyr52, Cys96-Asp99 and Cys105-Arg107; Fig. 2B). A striking difference between the two groups is the presence of the acidic residue Glu at position 128 in the C-terminal region of all SVPLA2s of the NB group, as opposed to a Lys or a Gly residue in the VS group. For the other groups, only CBa2 and Vbb contain a Glu at this position. With respect to the S group, the M group contains a conserved basic residue at position 115. Interestingly, the M group contains a conserved Lys in position 132 that is absent in the VS and NB groups. Group NB contains acidic side chains in the first strand of the beta-wing and the adjacent beta-turn (residues 75-82). For the VS and S groups, the tendency is towards a net balance of positive charges in the beta-wing.
###end p 33
###begin p 34
###xml 70 71 70 71 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 0 72 0 72 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Weblogo representation of the multiple sequence alignment of the SVPLA<sub>2</sub>s</bold>
###xml 93 98 93 98 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Catx </italic>
###xml 746 747 746 747 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
Weblogo representation of the multiple sequence alignment of the SVPLA2s. A. Group NB (AGTX, Catx and CbI). Each logo consists of stacks of symbols, one stack for each position in the sequence. The overall height of the stack indicates the sequence conservation at that position, while the height of symbols within the stack indicates the relative frequency of each amino acid at that position. The symbols in each stack are arranged by alphabetical order from top to bottom and do not follow the order in which the sequences were fed. Arg, His and Lys residues are in blue; Asp and Glu in red; Ala, Ile, Leu, Met, Phe, Pro, Trp, and Val in black; Gly, Cys, Ser, Thr, and Tyr, in green; Asn, Gln in purple. Renetseder numbering system for all PLA2s throughout this work [15]. B. Group VS (CBc and MtxII).
###end p 34
###begin p 35
###xml 13 18 13 18 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Catx </italic>
###xml 316 320 310 314 <italic xmlns:xlink="http://www.w3.org/1999/xlink">bAhp</italic>
The NB group Catx presents three Glu and one Asp residue in the beta-wing (residues 74-90); CbI presents two Asp residues. The beta-wing of CBc of group VS contains two Lys residues; that of MtxII two Lys, one Asp and one Glu residues. For the S and M groups the tendency is towards net positive charges, except for bAhp, for which the total charge is neutral.
###end p 35
###begin title 36
###xml 67 68 67 68 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
Tertiary structures and molecular electrostatic potentials of SVPLA2s
###end title 36
###begin p 37
###xml 42 43 42 43 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 65 68 65 68 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Vbb</italic>
###xml 130 132 130 132 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 217 219 213 215 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
###xml 476 477 461 462 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3</xref>
We obtained 3D homology models of CBc, CBa2, CbI, CbII, AtxA and Vbb. The models show the canonical structural features of the PLA2 template molecules: a N-terminal alpha-helix (helix A), a short helix (helix B), a Ca2+-binding loop, a long alpha-helix (C), a loop preceding an anti-parallel two-stranded sheet (beta-wing), a long alpha-helix (D), anti-parallel to helix C, and a C-terminal extended fragment. All seven disulfide-bridges are at their expected positions. Fig. 3 shows the molecular model of AtxA in the canonical ("front") face orientation, i.e., presenting the catalytic hydrophobic channel.
###end p 37
###begin p 38
###xml 0 45 0 45 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Ribbon diagram of the molecular model of AtxA</bold>
Ribbon diagram of the molecular model of AtxA. alpha-helices A, B, C and D, and the beta-wing are labeled. The seven-disulfide bridges are in yellow sticks and the His48/Asp99 pair in cyan sticks.
###end p 38
###begin p 39
###xml 5 7 5 7 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4A</xref>
###xml 78 79 78 79 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 109 111 109 111 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4B</xref>
###xml 258 259 258 259 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 327 330 327 330 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Vbb</italic>
###xml 359 361 359 361 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4A</xref>
###xml 430 434 430 434 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Vbb </italic>
###xml 440 442 440 442 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4B</xref>
###xml 557 559 557 559 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 579 583 579 583 <italic xmlns:xlink="http://www.w3.org/1999/xlink">bAhp</italic>
###xml 591 596 591 596 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Catx </italic>
###xml 605 606 605 606 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
Fig. 4A shows the MEP calculated at the molecular surface of the modeled SVPLA2s in the canonical view. Fig. 4B shows the MEP on the "back" face. Qualitatively, we observe that the MEP is positive in the front face of strong and mild anticoagulants (CBc, CBa2, CbII, and AtxA); approximately neutral for the weak anticoagulant Vbb, and negative for CbI (Fig. 4A). The back face is largely devoid of positive potential, except for Vbb (Fig. 4B). This difference in MEP leads to an electrostatic asymmetry. We observe the same trend for the crystallized SVPLA2 (MtxII, VRV-PLVIII, bAhp, AGTX, Catx and hsPLA2; not shown).
###end p 39
###begin p 40
###xml 72 82 72 82 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Viperidae </italic>
###xml 87 88 87 88 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 0 89 0 89 <bold xmlns:xlink="http://www.w3.org/1999/xlink">MEP at the solvent accessible surface of the 3D molecular models of the <italic>Viperidae </italic>SVPLA<sub>2</sub>s</bold>
###xml 127 128 127 128 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 151 154 151 154 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Vbb</italic>
MEP at the solvent accessible surface of the 3D molecular models of the Viperidae SVPLA2s. A. The models correspond to CBc, CBa2, AtxA, CbI, CbII, and Vbb. Color codes correspond to MEP in kT/e units: blue, +5; red, -5; white, 0. Front view. B. Back view.
###end p 40
###begin title 41
Molecular docking and intermolecular interfaces: mapping of the anticoagulant site and of the binding site on FXa
###end title 41
###begin p 42
###xml 263 265 263 265 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B39">39</xref>
###xml 1047 1048 1035 1036 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5</xref>
###xml 1159 1160 1147 1148 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F6">6</xref>
###xml 1263 1265 1251 1253 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 1318 1320 1306 1308 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4A</xref>
The output generated by the docking program PatchDock showed many complexes in contact with one of the binding site regions. Only the AtxA-FXa candidate complex (rank number 7) showed the best compatibility with the binding site derived from the mutagenesis data[39] (in this complex, position 150, which shows a Glu -> Arg sequence difference between the purchased FXa and the crystal structure (PDB entry 2BOH) is neither at the light/heavy chains interface nor at the AtxA/FXa interface). Several residues belonging to the two regions identified by the mutagenesis of AtxA and defining part of the binding site (the "front" strand of the beta-wing and the C-terminal fragment) are at the interface in this complex. In it, the relative orientation of FXa positions the N-terminus of the EGF-like 2 domain of the light chain of FXa towards the beta-wing of AtxA, allowing the 1-domain (not visible in the X-ray structure) to enter in interaction with the beta-wing and thus contact the remaining residues of the front edge of the beta-wing. Fig. 5 shows the ribbon representation of the final complex between AtxA and the light and heavy chains of FXa. Fig. 6 shows the same complex in the form of a solvent-accessible surface. In both representations, the SVPLA2 is in the "classical" orientation, i.e. that of Fig. 4A. Overall, we observe just small conformational changes after complex formation.
###end p 42
###begin p 43
###xml 0 113 0 113 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Ribbon representation of the 3D molecular model of the complex between AtxA and the light and heavy chains of FXa</bold>
###xml 358 361 358 361 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+ </sup>
Ribbon representation of the 3D molecular model of the complex between AtxA and the light and heavy chains of FXa. Crossed-eye stereo ribbon representation, with AtxA in green, the light and heavy chains of FXa in blue and purple, respectively. Catalytic site residues are red sticks for both AtxA (His48, Asp99) and FXa (His57, Ser102, Asp195). The metal Ca2+ ion of FXa is depicted as an orange sphere. The N- and C-ter of the AtxA, FXa's heavy chain and FXa's light chain are indicated.
###end p 43
###begin p 44
###xml 0 133 0 133 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Solvent-accessible surface representation of the 3D molecular model of the complex between AtxA and the light and heavy chains of FXa</bold>
Solvent-accessible surface representation of the 3D molecular model of the complex between AtxA and the light and heavy chains of FXa. Color coding as in Fig. 5.
###end p 44
###begin p 45
###xml 32 33 32 33 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 59 60 59 60 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 243 244 243 244 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
For the FXa strong-binding SVPLA2s CBc, MtxII, CbII and CBa2, the complexes that ranked 18, 10, 20 and 17, respectively, showed the same binding mode as the AtxA-FXa complex, i.e., the same relative orientation of FXa with respect to the SVPLA2. As measured by the FIT function of Pymol, these complexes showed Calpha RMSD's with respect to the reference AtxA-FXa complex of 3.4, 2.2, 5.1 and 4.8 A, respectively.
###end p 45
###begin p 46
###xml 100 101 100 101 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 163 164 163 164 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 186 188 186 188 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2 </sup>
###xml 208 210 208 210 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2 </sup>
###xml 281 282 281 282 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 484 486 484 486 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B72">72</xref>
###xml 494 495 494 495 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F7">7</xref>
###xml 526 527 526 527 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 591 592 591 592 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 785 786 785 786 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 1036 1039 1036 1039 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+ </sup>
###xml 1303 1309 1300 1306 <italic xmlns:xlink="http://www.w3.org/1999/xlink">et al.</italic>
###xml 1310 1312 1307 1309 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B73">73</xref>
###xml 1791 1793 1788 1790 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
###xml 1933 1934 1927 1928 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F8">8</xref>
The percentage of surface residues at the interface of the complexes is of 24-36% for the five SVPLA2s and of 20-32% for FXa. The interface area for the five SVPLA2s is in the 860-1700 A2 range and 915-1470 A2 for FXa. The interface area of the complexes varies from 1610 to 1930 A2. The values obtained for the solvent accessible area buried in the five characterized complexes fall between the small and the large interfaces categories in a study of 362 protein-protein interfaces [72]. Fig. 7 shows the mapping of the SVPLA2-FXa interaction surface of the complexes between the five SVPLA2s and FXa. The shadowed residues in that figure are those at the interface of the AtxA-FXa complex satisfying the mutagenesis data, and at the interface of the complexes of the other four SVPLA2s that show the same complexation mode as the AtxA-FXa complex. The consensus residues that participate to FXa binding are: solvent-exposed parts of helix A (positions 2, 3, 7) and helix B (positions 18, 19); positions 16, 23 and 24; a part of the Ca2+ loop (positions 31-34); a part of the 69-loop (between helix C and the beta-wing; positions 53, 59, 60, 69 and 70); and the C-terminal segment (positions 118, 119, 121-124, 129-131, 133). By taking into account the type of atom-atom contacts as defined by Sobolev et al.[73], 36.5% of the contacts are hydrophobic at the AtxA-FXa light chain interface, as compared to 26.4% at the AtxA-FXa heavy chain interface. Overall, 29.7% of the contacts are hydrophobic at the AtxA-FXa interface. These interface regions are identified separately by the protein-protein interface prediction server PPI-Pred. For example, for AtxA, the highest score PPI-Pred patch, which represents the most probable protein-protein binding site, includes helices A and B, the Ca2+-loop, part of the 69-loop, two residues from the front strand of the beta-wing, and the four C-terminal residues (results not shown). Fig. 8 shows the regions mapped by docking simulations in the modeled structure of complexed AtxA.
###end p 46
###begin p 47
###xml 0 15 0 15 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Viperidae SVPLA</italic>
###xml 15 17 15 17 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 0 48 0 48 <bold xmlns:xlink="http://www.w3.org/1999/xlink"><italic>Viperidae SVPLA</italic><sub>2 </sub>interface amino acid residues. </bold>
###xml 90 92 90 92 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 142 143 142 143 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 353 355 353 355 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
Viperidae SVPLA2 interface amino acid residues. Interface amino acid residues of the SVPLA2 complexes with FXa (CBc, MtxII, CbII, AtxA and CBa2). Underlined characters denote residues identified by mutagenesis to be critical for binding to FXa and inhibition of prothrombinase activity [39, 51]. Bold characters denote residues defining the IBS of hsPLA2 [13, 14]. Cyan-shadowed characters denote residues found at the interface of the selected complexes. The alignment reflects Renetseder's numbering system.
###end p 47
###begin p 48
###xml 0 88 0 88 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Ribbon diagram of the molecular model of AtxA showing the identified interface regions. </bold>
###xml 129 130 129 130 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 237 240 237 240 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+ </sup>
Ribbon diagram of the molecular model of AtxA showing the identified interface regions. The identified interface regions in SVPLA2s from Fig. 7 and made up of consensus positions 2, 3, 7 (helix A); 16; 18, 19 (helix B); 23, 24; 31-34 (Ca2+ loop); 53, 59, 60, 69, 70 (helix C-beta-wing loop); and 118, 119, 121-124, 129-131, 133 (C-terminal segment), are in red (see Results section).
###end p 48
###begin p 49
###xml 23 25 23 25 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F9">9A</xref>
###xml 30 32 30 32 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F9">9B</xref>
###xml 210 212 210 212 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F9">9A</xref>
###xml 330 332 330 332 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F9">9B</xref>
###xml 394 396 394 396 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F9">9A</xref>
###xml 401 403 401 403 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F9">9B</xref>
###xml 466 468 466 468 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 591 593 591 593 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 661 663 661 663 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F9">9B</xref>
###xml 786 788 786 788 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F9">9A</xref>
###xml 1121 1123 1121 1123 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F10">10</xref>
The first line of Fig. 9A and 9B show the amino acid sequences of the parts of the heavy and light chains of the crystal structure of FXa (PDB 2BOH), detected at the surface respectively. The heavy chain (Fig. 9A) includes the serine proteinase catalytic domain of FXa (catalytic-site residues in bold), and the light chain (Fig. 9B) includes the EGF-like 2 domain. The following lines in Fig. 9A and 9B show the FXa residues at the interface of the docked FXa-SVPLA2 complexes (residues appearing three or more times). The regions of FXa at the interface with CBc, MtxII, CbII, AtxA and CBa2 in the resulting docked complexes include, in the light chain (Fig. 9B), the N-terminal region of the EGF-like 2 domain: Arg86-Ser90 and Cys100-Glu102, Gln104, Asn105. In the heavy chain (Fig. 9A), they include the following regions. Region I: Arg93; Phe101 (from the 99-loop). Region II: Arg125; Asp126; Glu129-Ser130; Thr134. Region III: Tyr162; Asp164-Asn166; Lys169; Leu170. Region IV: Gln178 and Asn179 (from the 174-loop). Region V: Lys230, Thr232, Ala233, Phe234 and Lys236 (all residues from the C-terminal helix). Fig. 10 shows these regions in the 3D model of complexed FXa. Some of these residues belong to loops surrounding the catalytic-site cleft.
###end p 49
###begin p 50
###xml 0 33 0 33 <bold xmlns:xlink="http://www.w3.org/1999/xlink">FXa interface amino acid residues</bold>
###xml 148 149 148 149 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 379 380 379 380 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 461 463 461 463 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 612 613 612 613 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
FXa interface amino acid residues. A. Amino acid residues of the heavy chain of FXa at the interface of the selected docked complexes for each SVPLA2. The sequence of FXa shows only residues detected in the X-ray experiment. The last line shows the experimentally reported residues of FXa involved in the binding to FVa [2, 78, 79, 83]. We use Renetseder's notation for the SVPLA2s and chymotrypsinogen notation for FXa. The sequences of CBc, AtxA, CbII and CBa2 were aligned with respect to MtxII. B. Amino acid residues of the light chain of FXa at the interface of the selected docked complexes for each SVPLA2.
###end p 50
###begin p 51
###xml 0 98 0 98 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Ribbon diagram of the crystal structure of FXa (PDB 2BOH) showing the identified interface regions</bold>
Ribbon diagram of the crystal structure of FXa (PDB 2BOH) showing the identified interface regions. The figure highlights in red the regions corresponding to the identified interface residues from Fig. 9A and B. In the light chain: Arg86-Ser90 and Cys100-Asn105. In the heavy chain: Region I: Arg93; Phe101 (from the 99-loop). Region II: Arg125; Asp126; Glu129-Ser130; Thr134. Region III: Tyr162; Asp164-Asn166; Lys169; Leu170. Region IV: Gln178 and Asn179 (from the 174-loop). Region V: Lys230, Thr232, Ala233, Phe234 and Lys236 (residues from the C-terminal helix). Only residues present three or more times in the same column in the sequences are included. Light chain is in blue, heavy chain in purple. FXa is rotated 90degrees in a clockwise sense about its vertical axes with respect to Fig. 5. The terminal ends of FXa's chains are labeled. The catalytic triad is represented as cyan sticks.
###end p 51
###begin p 52
###xml 16 19 16 19 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F11">11A</xref>
###xml 24 27 24 27 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F11">11B</xref>
###xml 150 151 150 151 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 253 254 253 254 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 275 278 275 278 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+ </sup>
###xml 407 410 404 407 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F11">11A</xref>
###xml 557 560 551 554 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F11">11B</xref>
###xml 642 644 636 638 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 934 937 928 931 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F11">11A</xref>
We show in Fig. 11A and 11B the intermolecular residue contacts for the AtxA-FXa interface for which the contact area is equal to or greater than 10 A2. We observe from this map that the heavy chain of FXa interacts with the following regions of the PLA2: a portion of the Ca2+ loop, the helix C-beta-wing loop, and the C-terminal segment (including Lys127, which has an effect in the binding to FXa) (Fig. 11A). The light chain of FXa establishes intermolecular contacts with the remaining regions: helices A and B, and the beta-wing (Arg77) of AtxA (Fig. 11B). From the CSU analysis of interfaces, it follows that the contacts between SVPLA2 and FXa are of diverse nature -aromatic-aromatic, hydrophobic-hydrophobic, salt bridges and H-bonds. There are also destabilizing hydrophobic-hydrophilic interactions. Few of the contacts take place between same-nature residues, like Lys127 from AtxA and Arg93 from FXa's heavy chain (Fig. 11A). These contacts are between non-polar atoms or between non-polar and polar atoms of side chains at the surface of the molecules, where the presence of the aqueous solvent can buffer the electrostatic interactions.
###end p 52
###begin p 53
###xml 0 36 0 36 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Contact map for the AtxA-FXa complex</bold>
###xml 137 138 137 138 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
Contact map for the AtxA-FXa complex. A. Heavy-chain FXa residues. Only residues for which the contact area is equal or greater than 10 A2 are shown.B. Light-chain FXa residues.
###end p 53
###begin title 54
Discussion
###end title 54
###begin title 55
Existence of different anticoagulant mechanisms
###end title 55
###begin p 56
###xml 92 94 92 94 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 473 474 473 474 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 653 654 653 654 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 666 679 666 679 <italic xmlns:xlink="http://www.w3.org/1999/xlink">N. nigricolis</italic>
###xml 689 711 689 711 <italic xmlns:xlink="http://www.w3.org/1999/xlink">V. ammodytes ammodytes</italic>
###xml 722 723 722 723 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 837 839 837 839 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 844 854 844 854 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Viperidae </italic>
###xml 1031 1033 1031 1033 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 1107 1112 1107 1112 <italic xmlns:xlink="http://www.w3.org/1999/xlink">bAhp </italic>
###xml 1116 1120 1116 1120 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Vbb </italic>
###xml 1339 1344 1339 1344 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Catx </italic>
###xml 1509 1511 1509 1511 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 1512 1514 1512 1514 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B38">38</xref>
###xml 1581 1583 1581 1583 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B74">74</xref>
###xml 689 711 <span type="species:ncbi:8705">V. ammodytes ammodytes</span>
The classification of the anticoagulant potency (strong, weak, non-anticoagulant) of a SVPLA2 depends on the anticoagulant assay used and on whether this assay leads to establishing the mechanism of action. Usually, the recalcification time assay, one of the simplest assays, is used. This method is very sensitive to the lipid levels in the plasma but does not show whether the mechanism is PL-independent or not. Our results deal with the interaction of anticoagulant PLA2s with FXa through the non-catalytic, PL-independent mechanism of action and are to be compared to studies performed under the same conditions. As mentioned before, only three PLA2s -CM-IV of N. nigricolis, AtxA of V. ammodytes ammodytes, and hsPLA2- have been studied under these conditions. In this work, we complete these studies by testing several other SVPLA2 from Viperidae venom. Our results clearly show that CBc and MtxII interact with FXa with very high affinity and strongly inhibit the formation of the prothrombinase complex. CbII, AtxA and CBa2 possess good affinity for FXa and good anticoagulant potency. VRV-PLVIII, bAhp and Vbb possess weak affinity for FXa and show weaker inhibition of prothrombinase activity. Some of these enzymes (CB, AtxA) also inhibit prothrombinase activity in the presence of PL (not shown). AGTX, the CA subunit of CTX, Catx and CbI do not interact with FXa and do not inhibit prothrombinase activity in the absence of PL. Therefore, AGTX, described previously as a weakly anticoagulant PLA2 [38], and VRV-PLVIII, described previously as strongly anticoagulant [74], appear to inhibit blood coagulation through different mechanisms.
###end p 56
###begin title 57
Search for an anticoagulant site
###end title 57
###begin title 58
###xml 53 62 53 62 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Viperidae</italic>
###xml 68 69 68 69 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
Possible location of an anticoagulant site common to Viperidae SVPLA2s that interact directly with FXa
###end title 58
###begin p 59
###xml 67 68 67 68 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 96 98 96 98 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 493 494 493 494 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 560 563 560 563 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+ </sup>
###xml 669 671 663 665 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 677 678 671 672 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F8">8</xref>
###xml 780 781 774 775 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
Reduced and carboxymethylated CBc did not interact with FXa (Table 1), suggesting that the SVPLA2 needs to adopt the proper conformation for the interaction to take place. In agreement and in the context of the PL-independent anticoagulant mechanism, our combined theoretical and experimental approach highlights the presence of an anticoagulant region composed of amino acid residues that come together in space to constitute a conformational epitope situated in the "front" face of the SVPLA2s. These are the solvent-exposed parts of helix A, helix B, the Ca2+ loop, the helix C-beta-wing loop, the front strand of the beta-wing, and the C-terminal segment of the PLA2 (Fig. 8). Of course, the detailed distribution and composition of those residues varies for each of the SVPLA2s.
###end p 59
###begin p 60
###xml 10 16 10 16 <italic xmlns:xlink="http://www.w3.org/1999/xlink">et al.</italic>
###xml 17 19 17 19 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B52">52</xref>
###xml 76 78 76 78 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 90 109 90 109 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Vipera r. russelli </italic>
###xml 164 165 164 165 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 439 440 439 440 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 465 471 465 471 <italic xmlns:xlink="http://www.w3.org/1999/xlink">et al.</italic>
###xml 472 474 472 474 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B75">75</xref>
###xml 519 524 519 524 <italic xmlns:xlink="http://www.w3.org/1999/xlink">bAhp </italic>
###xml 601 602 601 602 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 624 630 624 630 <italic xmlns:xlink="http://www.w3.org/1999/xlink">et al.</italic>
###xml 631 633 631 633 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B76">76</xref>
###xml 676 681 676 681 <italic xmlns:xlink="http://www.w3.org/1999/xlink">bAhp </italic>
###xml 973 975 973 975 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 981 982 981 982 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F8">8</xref>
###xml 1063 1064 1063 1064 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 1100 1102 1100 1102 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B48">48</xref>
Carredano et al.[52] determined the 3D structure of group II A monomeric PLA2 RVV-VD from Vipera r. russelli (PDB 1VIP), described as a strongly anticoagulant SVPLA2. The authors proposed a site responsible for the strong anticoagulant properties of the toxin, consisting of Glu53, together with a positively charged ridge of non H-bonded lysine residues free for intermolecular interactions in the 53-70 region (Lys60 in RVV-VD and in CBa2). On another hand, Zhao et al.[75] suggested that residues Trp70 and Glu53 in bAhp might play an important role in the anticoagulant activity of the basic SVPLA2s. The study of Zhong et al.[76], who tested the anticoagulant potency of bAhp mutants, revealed that the Glu53Gly and Trp70Met mutants lost their effects on blood clotting, while Thr56Lys and Asp67Lys had enhanced activity. The reported residues fall in the 53-70 interface region detected in our docked complexes of the strong FXa binders CBc, MtxII, CbII, AtxA and CBa2 (Fig. 8). The possible contribution of Trp70 to the strong anticoagulant activity of PLA2s has also been proposed elsewhere [48]. Nevertheless, the anticoagulant region cannot be localized solely to the 53-70 segment, since enzymes that bind weakly or not at all to FXa contain also basic residues in this region.
###end p 60
###begin p 61
###xml 31 33 31 33 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 144 147 144 147 <sub xmlns:xlink="http://www.w3.org/1999/xlink">50 </sub>
###xml 202 204 202 204 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
The natural mutants CBc and CBa2 present two Gly -> Glu mutations in the C-terminal region (Gly116Glu, Gly128Glu) leading to increases in the IC50 values for inhibition of prothrombinase activity of CBa2 with respect to CBc. This is consistent with the results of our sequence comparison analysis, in which we detect the acidic residue at position 128 as characteristic of the NB group, and with the docking results that point to this region as being at the interface of the complexes.
###end p 61
###begin p 62
###xml 65 67 65 67 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 203 205 203 205 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B51">51</xref>
###xml 421 422 421 422 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F7">7</xref>
###xml 624 626 618 620 <sub xmlns:xlink="http://www.w3.org/1999/xlink">50</sub>
###xml 706 707 697 698 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 741 744 732 735 <sub xmlns:xlink="http://www.w3.org/1999/xlink">50 </sub>
###xml 837 840 828 831 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+ </sup>
###xml 907 909 895 897 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 915 916 903 904 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F7">7</xref>
On the other hand, we localized in the crystal structure of hsPLA2 (PDB 1BBC) the mutations that showed the major effects in the inhibition of prothrombinase activity and FXa-binding kinetic parameters [51]. Residues Arg7, Lys10 and Lys16 (helix A) are exposed to the solvent and form a cluster. Residue Lys38 (loop on N-terminus of helix B), and residues Lys123 and Arg126 form another cluster (underlined residues Fig. 7). As expected, the two clusters are situated on the front face and are oriented 180degrees about this convex surface. They act cooperatively in the binding to FXa. Lys86 carries with it an effect on IC50, but is in the end of the second strand of the beta-wing ("back" face) of hsPLA2, indicating that its effect on IC50 is not due to the residue being at the interface. No effects are reported dealing with the Ca2+ loop and the front strand of the beta-wing does not appear in hsPLA2 (Fig. 7); however, to our knowledge, these regions have not yet been probed.
###end p 62
###begin p 63
###xml 224 225 224 225 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
Lastly, our experimental data suggest that the CB-FXa interaction site is different from the CB-CA interface and show that the interaction between FXa and CTX proceeds through a transient ternary (CA, CB, FXa) complex (Fig. 1).
###end p 63
###begin title 64
###xml 29 31 29 31 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
The FXa binding region of PLA2 involves also hydrophobic residues
###end title 64
###begin p 65
###xml 5 7 5 7 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 137 139 137 139 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 178 180 178 180 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 193 195 193 195 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 200 225 200 225 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Agkistrodon p. piscivorus</italic>
###xml 280 282 280 282 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 352 354 352 354 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 562 565 562 565 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+ </sup>
###xml 579 581 579 581 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B77">77</xref>
###xml 642 644 642 644 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 673 676 673 676 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+ </sup>
###xml 677 679 677 679 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B50">50</xref>
###xml 920 930 920 930 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Viperidae </italic>
###xml 935 936 935 936 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 950 951 950 951 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 1089 1090 1089 1090 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 1445 1446 1445 1446 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F7">7</xref>
###xml 1557 1559 1557 1559 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B39">39</xref>
###xml 157 163 <span type="species:ncbi:9913">bovine</span>
hsPLA2 contains an unusually large number of prominent cationic patches on its molecular surface, some of which lie on the putative IBS [14], in contrast to bovine pancreatic PLA2 and the SVPLA2 from Agkistrodon p. piscivorus, which display only a limited number of such patches [10]. Given the charged nature of the residues critical for binding hsPLA2 and AtxA to FXa, it is clear that electrostatic interactions play a role in the binding. Indeed, the electrostatic asymmetry showed by the MEP calculations must be enhanced by the presence of the essential Ca2+ cofactor ion [77] and may be at the origin of the increased affinity of hsPLA2 for FXa in the presence of Ca2+ [50]. Thus, long distance electrostatic forces operating at the molecular surface are important and may optimally orient the molecules before binding to FXa. However, electrostatic interactions might not exclusively drive binding to FXa by the Viperidae SVPLA2s, as in hsPLA2. Indeed, in addition to basic residues, hydrophobic and aromatic residues play also key roles in optimizing the interaction between SVPLA2s and FXa, given that a ring of hydrophobic residues surrounds the opening to the catalytic site cavity. Thus, for AtxA, many hydrophobic residues (Leu2, 3, 10, 18 and 58; Pro17, 59, 68 and 121; Val31), most of which are located in the N-terminal region, and several aromatic residues (Phe24 and 123; Tyr52) are part of the surface presented to FXa (Fig. 7). Lastly, even though a Phe24Ala mutation in AtxA was not found to change the FXa-binding kinetic parameters [39], we emphasize the need to probe other residues belonging to the hydrophobic ring.
###end p 65
###begin title 66
###xml 7 9 7 9 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
The PLA2 binding region of FXa involves both, the light and heavy chains but not the catalytic site
###end title 66
###begin p 67
###xml 186 188 186 188 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 189 191 189 191 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B51">51</xref>
###xml 302 304 302 304 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 377 378 377 378 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5</xref>
###xml 520 521 517 518 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 658 659 655 656 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 838 840 835 837 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B51">51</xref>
###xml 1033 1034 1030 1031 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 1261 1262 1255 1256 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 939 945 <span type="species:ncbi:9913">bovine</span>
###xml 989 995 <span type="species:ncbi:9913">bovine</span>
On our results, the catalytic site of FXa is free and not involved in the interface, in agreement with the conservation of the serine-proteinase catalytic activity after binding by SVPLA2 [51]. Our AtxA-FXa complex shows that one region of the light chain of FXa is involved in the binding to the SVPLA2 and that the N-terminus of the EGF-like 2-domain is pointing south (Fig. 5). Therefore, the EGF-like 1-domain, not visible in the crystal structure of FXa, can interact with the front edge of the beta-wing of the PLA2. The Gla domain of FXa (bound to the N-terminus of the EGF-like 1-domain), is well beyond reach in space and not in contact with the PLA2. These two features are in agreement with experimental and biochemical data which support the conclusion that the Gla domain is needed rather for insertion into the PL membrane [51], and with a model of the entire FXa. Indeed, based on the crystal structure of the Gla domain of bovine prothrombin and the NMR coordinates of the bovine FX EGF1 domain, Bajaj and coworkers [2] proposed a model structure for the entire FXa molecule, based upon the crystal structure of porcine FIXa. The EGF domains in the model are oriented south and thus capable of establishing contacts with the beta-wing of the PLA2.
###end p 67
###begin p 68
###xml 171 173 171 173 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F9">9A</xref>
###xml 330 332 330 332 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B78">78</xref>
###xml 356 358 356 358 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B79">79</xref>
###xml 359 361 359 361 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B81">81</xref>
###xml 401 403 401 403 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B82">82</xref>
###xml 426 428 426 428 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B83">83</xref>
###xml 448 450 448 450 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B81">81</xref>
###xml 603 613 603 613 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Viperidae </italic>
###xml 618 619 618 619 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 712 714 712 714 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F9">9A</xref>
###xml 782 783 782 783 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 971 972 971 972 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
Based on the ability of synthetic peptides from FXa to inhibit FXa-induced clotting, a number of authors have reported the FVa binding sites on FXa. The last line of Fig. 9A shows the experimentally reported residues of the heavy chain of FXa incontrovertibly involved in the binding to FVa. These residues are: FXa(His83-Lys96) [78]; FXa(Arg165, Lys169) [79-81]; the 185-189 loop, i.e., FXa(Lys186) [82]; FXa(Val231-Thr244) [83]; and FXa(Arg240) [81]. Three of four of the segments of the catalytic domain of FXa identified to interact with FVa overlap with those identified by us to interact with the Viperidae SVPLA2s, namely the segment about Lys90, the 162-loop, and the C-terminal part, about Lys237 (Fig. 9A). This suggests that several residues are shared by both, the SVPLA2-FXa and the FVa-FXa binding interfaces. Moreover, the experimentally identified FXa heavy chain residues involved in binding to FVa are located on the same 3D face of FXa, as in our SVPLA2-FXa complexes.
###end p 68
###begin p 69
###xml 172 174 172 174 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B84">84</xref>
###xml 175 177 175 177 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B85">85</xref>
###xml 524 525 514 515 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 533 535 523 525 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F9">9A</xref>
###xml 540 542 530 532 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F10">10</xref>
###xml 68 73 <span type="species:ncbi:9606">human</span>
Arni and coworkers have recently reported the crystal structures of human Gla domainless FXa complexed with two small anticoagulant proteins from a hematophagous nematode [84,85]. The determined exosite from those complexes involves residues from one of the strands of the N-terminal seven-stranded beta-barrel (strand beta6, residues 80-93) and from the short C-terminal alpha-helix (residues 233-243) of the catalytic subunit of FXa. Several of these residues fall in regions I and V mapped in our complexes with the SVPLA2s (Fig. 9A and 10).
###end p 69
###begin title 70
###xml 79 80 79 80 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
Several IBS residues are part of the PL-independent anticoagulant site of SVPLA2
###end title 70
###begin p 71
###xml 44 46 44 46 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 47 49 47 49 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 137 139 137 139 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 166 168 166 168 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B51">51</xref>
By combining the residues defining the IBS [13,14] with the site-directed mutagenesis experiments for probing the basic residues of hsPLA2 involved in binding to FXa[51], we deduce that IBS residues Arg7 and Lys10 bind to FXa.
###end p 71
###begin p 72
###xml 22 23 22 23 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 197 199 197 199 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B39">39</xref>
By homology with hsPLA2, the presumed IBS amino acid residues for AtxA are Leu3, Leu18, Phe24, Lys74 and Tyr113. On one hand, Lys74, experimentally found to be critical for binding of AtxA to FXa [39], belongs to the IBS. On the other hand, our simulations indicate that IBS residues Leu3, Leu18 and Phe24 are in contact with FXa. In conclusion, several IBS residues are part of the PL-independent anticoagulant site and participate in formation of the complex with FXa.
###end p 72
###begin title 73
###xml 5 7 5 7 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
SVPLA2 are multifunctional proteins with multiple pharmacological sites
###end title 73
###begin p 74
###xml 4 14 4 14 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Viperidae </italic>
###xml 19 20 19 20 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 171 173 171 173 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B86">86</xref>
###xml 185 187 185 187 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B52">52</xref>
###xml 362 364 362 364 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B39">39</xref>
###xml 395 397 395 397 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B87">87</xref>
The Viperidae SVPLA2s studied here are multifunctional proteins, raising the possibility of overlapping or multiple pharmacological sites distinct from the catalytic site[86]. One team[52] has suggested that the neurotoxic site of group II neurotoxic enzymes overlaps with the anticoagulant region. Thus, from the mutants used to test the anticoagulant potency [39] and the neurotoxic function [87] of AtxA, it appears that several residues in the C-terminus are clearly shared by both functions. The overlapping of pharmacological sites is most easily understood in terms of the small size of this family of proteins.
###end p 74
###begin title 75
Conclusion
###end title 75
###begin p 76
###xml 76 86 76 86 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Viperidae </italic>
###xml 91 92 91 92 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 372 374 372 374 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 197 202 <span type="species:ncbi:9606">human</span>
In this paper, we concentrated our efforts on identifying the anticoagulant Viperidae SVPLA2s that inhibit blood coagulation via a non-enzymatic, PL-independent mechanism through direct binding to human FXa. Using SPR technology, we showed that CBc and MtxII bind to FXa with the highest affinity and inhibit strongly the prothrombinase complex, whereas CbII, AtxA and CBa2 bind with good, but lesser affinity.
###end p 76
###begin p 77
###xml 54 55 54 55 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 75 78 75 78 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+ </sup>
###xml 364 366 364 366 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
Of the eight mutations that differentiate CBc from CBa2, Arg34Gln in the Ca2+ loop and Gly128Glu in the C-terminal segment fall in our identified interface regions; Gly116Glu is just borderline to the C-terminal fragment. Thus, the disappearance of a positive charge and the appearance of two negative charges in this region account for the loss of affinity of CBa2 for FXa with respect to CBc. This is consistent with our consensus sequence analysis, which had associated the presence of Glu at position 128 to a decrease in affinity.
###end p 77
###begin p 78
###xml 156 157 156 157 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 192 194 192 194 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 221 223 221 223 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B44">44</xref>
###xml 256 258 256 258 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
The molecular electrostatic potential we calculate at the surface of the 3D molecular models shows a correlation with the anticoagulant potency of the SVPLA2s. However, since not all basic PLA2 are strong anticoagulants [44], the basic character of the PLA2 seems to be a necessary but not sufficient condition for its anticoagulant potency.
###end p 78
###begin p 79
###xml 67 68 67 68 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 252 253 252 253 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 502 505 499 502 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+ </sup>
Mapping of the FXa-interface zone in the 3D structures of the SVPLA2s by binding-site directed docking simulations, allowed us to detect several FXa-binding regions that come together to form a conformational epitope on the "front" surface of the SVPLA2s. One of the regions maps to the 53-70 segment, proposed in the past to be the anticoagulant region. According to our findings, this region is to be extended, on one hand, to helices A and B and to the "front" strand of the beta-wing, and to the Ca2+ loop and the C-terminal direction, on the other. The FXa interface forms a novel exosite that involves both, the light and heavy chains.
###end p 79
###begin p 80
Our work epitomizes the use of binding affinity and mutational experimental data in guiding molecular docking simulations by indicating which species associate and then outlining the possible interacting surface patches.
###end p 80
###begin p 81
###xml 134 144 134 144 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Viperidae </italic>
###xml 149 150 149 150 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 328 330 328 330 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 569 577 569 577 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo </italic>
Finally, there has been intense interest in the development of FXa inhibitors for the treatment of thrombotic diseases. Anticoagulant Viperidae SVPLA2s, which interact with FXa via a non-catalytic, PL-independent mechanism, represent a novel family of selective FXa inhibitors. Structural information on the binding of these PLA2 to FXa should be useful in the 3D structure-based design of therapeutic agents. The synthesis of peptides or peptidomimetics derived from our mapped regions could lead to the development of new antithrombotic molecules capable of delaying in vivo the activation stage of the prothrombinase complex and to their use as supplementary agents in antithrombotic therapy.
###end p 81
###begin title 82
Methods
###end title 82
###begin p 83
###xml 87 88 87 88 <italic xmlns:xlink="http://www.w3.org/1999/xlink">N</italic>
###xml 115 116 115 116 <italic xmlns:xlink="http://www.w3.org/1999/xlink">N</italic>
###xml 123 125 123 125 <italic xmlns:xlink="http://www.w3.org/1999/xlink">N'</italic>
###xml 453 475 453 475 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pseudocerastes fieldi </italic>
###xml 561 563 561 563 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B88">88</xref>
###xml 576 603 576 603 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Vipera ammodytes ammodytes </italic>
###xml 648 650 648 650 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 705 707 705 707 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B89">89</xref>
###xml 753 755 753 755 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 775 777 775 777 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 836 862 836 862 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Daboia russelli pulchella </italic>
###xml 925 927 925 927 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B55">55</xref>
###xml 928 930 928 930 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B56">56</xref>
###xml 931 933 931 933 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B62">62</xref>
###xml 934 936 934 936 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B67">67</xref>
###xml 1054 1060 1054 1060 <italic xmlns:xlink="http://www.w3.org/1999/xlink">et al.</italic>
###xml 1061 1063 1061 1063 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B56">56</xref>
###xml 1277 1279 1277 1279 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 1284 1302 1284 1302 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Vipera berus berus</italic>
###xml 1307 1309 1307 1309 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 1314 1328 1314 1328 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Crotalus atrox</italic>
###xml 1352 1354 1352 1354 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 1359 1384 1359 1384 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Agkistrodon hallys pallas</italic>
###xml 1401 1415 1401 1415 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Bothrops asper</italic>
###xml 1856 1858 1856 1858 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B90">90</xref>
###xml 2340 2343 2340 2343 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+ </sup>
###xml 453 474 <span type="species:ncbi:47769">Pseudocerastes fieldi</span>
###xml 576 602 <span type="species:ncbi:8705">Vipera ammodytes ammodytes</span>
###xml 836 861 <span type="species:ncbi:97228">Daboia russelli pulchella</span>
###xml 1284 1302 <span type="species:ncbi:31156">Vipera berus berus</span>
###xml 1314 1328 <span type="species:ncbi:8730">Crotalus atrox</span>
###xml 1401 1415 <span type="species:ncbi:8722">Bothrops asper</span>
###xml 1444 1449 <span type="species:ncbi:9606">human</span>
Reagents including Sensor Chips CM5, surfactant P20, the amine coupling kit containing N-hydroxysuccinimide (NHS), N-ethyl-N'-(3-diethylaminopropyl)carbodiimide (EDC) and ethanolamine hydrochloride were supplied by Biacore (Biacore AB, Uppsala, Sweden). All other chemicals and solvents of the highest available purity were obtained from either Merck A.G. (Darmstad, Germany), Prolabo (Paris, France) or Sigma Co (St. Louis, MO, USA). CbI and CbII from Pseudocerastes fieldi venom were supplied by Dr. A. Bdolah (Dept. of Zoology, Tel Aviv University, Israel) [88]. AtxA from Vipera ammodytes ammodytes was purchased from Latoxan. Recombinant hsPLA2 was produced in our laboratory as described previously[89]. Isoforms of the CB subunit of crotoxin (CBa2 and CBc), isoform CA2 of the acidic subunit of crotoxin, and the VRV-PLVIII from Daboia russelli pulchella venom were purified in our laboratory as described previously [55,56,62,67]. CBc was reduced by dithiothreitol and alkylated with iodoacetic acid according to the procedure described by Faure et al.[56]. Drs. I. Krizaj (Institute Jozef Stefan, Ljubliana), E. Myatt (Argon Institute), Y. C. Chen (Institut of Biochemistry, Shanghai, China), and J. Perales (Fundacao Oswaldo Cruz, Rio de Janeiro, Brazil) provided PLA2 from Vipera berus berus, PLA2 from Crotalus atrox, AGTX and the basic PLA2 from Agkistrodon hallys pallas, and MtxII from Bothrops asper, respectively. We purchased human activated blood coagulation factor (FXa) from Enzyme Res. Laboratories, USA (MW 46 kDa). The corresponding amino acid sequence shows a Glu residue at position 150 of the heavy chain, whereas UniProt's entry P00742 (FA10_HUMAN) shows an Arg. This residue is at the surface of the molecule. For the simulations, we chose the 2.2 A resolution crystallographic structure of Gla-domainless FXa from entry 2BOH [90] of the PDB, which corresponds to sequence FA10_HUMAN and is made up of the heavy chain and of the EGF-like 1 and 2 domains of the light chain. Only light chain residues Arg86-Glu138, which represent the EGF-like 2 domain, and heavy chain residues Ile16-Thr244 are located in the X-ray diffraction experiment -the entire EGF-like 1 domain and its hydrophobic peptide preceding it being disordered. In this structure, FXa is co-crystallized with a 2-carboxyindole inhibitor and a Ca2+ ion chelated by Asp70, Asn72, Gln75 and Glu80 of the catalytic (heavy) chain. We removed the inhibitor and the water molecules for the calculations.
###end p 83
###begin p 84
We performed computer graphics using PyMOL (DeLano Scientific LLC, San Francisco, CA, USA), and the insightII and DS Visualizer softwares (Accelrys Inc, San Diego, CA, USA). Computer calculations were performed with the insightII software package on SGI graphic stations and using programs available in servers in the World Wide Web with PC workstations.
###end p 84
###begin title 85
Determination of prothrombinase activity
###end title 85
###begin p 86
###xml 52 53 52 53 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 68 77 68 77 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 122 124 122 124 <sub xmlns:xlink="http://www.w3.org/1999/xlink">50</sub>
###xml 138 147 138 147 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 292 294 286 288 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+</sup>
###xml 327 329 321 323 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B39">39</xref>
###xml 431 432 425 426 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 575 576 563 564 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 724 726 712 714 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B50">50</xref>
###xml 775 778 763 766 <sub xmlns:xlink="http://www.w3.org/1999/xlink">50 </sub>
###xml 867 868 855 856 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 245 250 <span type="species:ncbi:9606">human</span>
We determined the anticoagulant potency of the SVPLA2s by measuring in vitro the inhibition of prothrombinase activity (IC50). We used an in vitro biological test in which the prothrombinase complex was reconstituted at 37degreesC from purified human factors FVa and FXa in the presence of Ca2+, but without the addition of PL[39]. The purified prothrombinase components (FVa 10 nM, FXa 10 nM, and different concentrations of SVPLA2: 0, 10, 20, 50, 100, 200, 500 nM) were incubated 5 min at 37degreesC in Tris-buffered saline (0.05 M Tris/HCl, 0.1 M NaCl, 0.5% BSA, 5 mM CaCl2, pH 7.4). The reaction was then started with 110 nM prothrombin. We measured activated prothrombin activity every 20 min, as described previously [50], with small modifications. We determined the IC50 value, which corresponds to 50% inhibition of thrombin generation for the different SVPLA2s in the absence of PL.
###end p 86
###begin title 87
Surface Plasmon Resonance studies
###end title 87
###begin p 88
###xml 48 49 48 49 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 60 70 60 70 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Viperidae </italic>
###xml 108 112 108 110 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#174; </sup>
###xml 257 258 255 256 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 448 454 440 446 <italic xmlns:xlink="http://www.w3.org/1999/xlink">et al.</italic>
###xml 455 457 447 449 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B39">39</xref>
###xml 751 753 743 745 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2 </sup>
###xml 793 795 785 787 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 1090 1092 1073 1075 <sub xmlns:xlink="http://www.w3.org/1999/xlink">d </sub>
###xml 1092 1095 1075 1078 <sup xmlns:xlink="http://www.w3.org/1999/xlink">app</sup>
###xml 1101 1104 1084 1087 <sub xmlns:xlink="http://www.w3.org/1999/xlink">off</sub>
###xml 1108 1110 1091 1093 <sub xmlns:xlink="http://www.w3.org/1999/xlink">on</sub>
###xml 1154 1157 1137 1140 <sub xmlns:xlink="http://www.w3.org/1999/xlink">off</sub>
###xml 1203 1205 1186 1188 <sub xmlns:xlink="http://www.w3.org/1999/xlink">on</sub>
###xml 1453 1454 1434 1435 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 338 343 <span type="species:ncbi:9606">Human</span>
We analyzed of the interaction between the SVPLA2s from the Viperidae family, and FXa by SPR using a BIACORE(R) 2000 system (Biacore AB, Uppsala, Sweden). The running and dilution buffer in all experiments was Hepes (HBS; 10 mM Hepes, 150 mM NaCl, 5 mM CaCl2, 0.005% surfactant P20, pH 7.4). The experiments were conducted at 37degreesC. Human FXa was covalently coupled via primary amino groups on a CM5 sensor chip surface according to Prijatelj et al.[39]. One independent flow cell of the same sensor chip was used as a control flow cell and was subjected to a "blank immobilization," i.e., with no FXa added. We found the SPR signal for immobilized FXa on three different flow cells to be 1500 RU, 3000 RU and 5840 RU (1 RU corresponds to 1 pg/mm2 of immobilized protein). We injected PLA2 samples (0, 0.25, 0.5, 1, 2, 4, and 8 mug/ml) at 37degreesC with a flow rate of 20 mul/min on independent runs on the control and assay flow cells and their binding was monitored. Between each injection, we regenerated surfaces with twice 5 muL of 1 M NaCl. The apparent equilibrium constant, <Kd app> = <koff>/<kon>, the average dissociation rate constant <koff> and the average association rate constant <kon> were calculated using Biacore's BIAevaluation 3 software. The kinetic models used to fit the data included the Langmuir association, heterogeneous analyte and conformational change. Only the first one showed the lowest closeness-of-fit value (chi2). In addition, the other models resulted in affinities much lower (muM) than expected (nM).
###end p 88
###begin title 89
Sequence homologies and alignments
###end title 89
###begin p 90
###xml 102 104 102 104 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 176 179 176 179 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Vbb</italic>
###xml 206 208 206 208 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B57">57</xref>
###xml 229 231 229 231 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B57">57</xref>
###xml 248 250 248 250 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 251 253 251 253 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B56">56</xref>
The sequence databases and identifiers are the following: CBc (also known as CB1), Uniprot P62022; CBa2 (also known as CB2), P24027; AGTX, P14421; AtxA, P00626; MtxII, P24605; Vbb, P31854; CbI, gi 1345182 [57]; CbII, gi 1345181 [57]; CA, isoform CA2 [56](obtained by post-translational modification of ProCA, P08878).
###end p 90
###begin p 91
###xml 53 55 53 55 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B91">91</xref>
###xml 56 58 56 58 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B92">92</xref>
###xml 289 291 289 291 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B93">93</xref>
###xml 292 294 292 294 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B94">94</xref>
For sequence alignments, we used the LALIGN program [91,92], which finds multiple matching sub-segments in two sequences and shows the local sequence alignments. For representing sequences and their alignments, we used Weblogo, a web-based application designed to generate sequence logos [93,94].
###end p 91
###begin title 92
Molecular modeling
###end title 92
###begin p 93
###xml 50 51 50 51 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 68 69 68 69 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 184 185 184 185 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 319 320 319 320 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 396 398 396 398 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B95">95</xref>
###xml 449 451 449 451 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 456 480 456 480 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Agkistrodon halys pallas</italic>
###xml 481 483 481 483 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B96">96</xref>
###xml 490 494 490 494 <bold xmlns:xlink="http://www.w3.org/1999/xlink">1A2A</bold>
###xml 516 518 516 518 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 523 548 523 548 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Daboia russelli pulchella</italic>
###xml 549 551 549 551 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B97">97</xref>
###xml 558 562 558 562 <bold xmlns:xlink="http://www.w3.org/1999/xlink">1FB2</bold>
###xml 594 596 594 596 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 601 615 601 615 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Bothrops asper</italic>
###xml 618 620 618 620 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B98">98</xref>
###xml 627 631 627 631 <bold xmlns:xlink="http://www.w3.org/1999/xlink">1CLP</bold>
###xml 641 643 641 643 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 648 662 648 662 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Crotalus atrox</italic>
###xml 663 665 663 665 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B99">99</xref>
###xml 672 676 672 676 <bold xmlns:xlink="http://www.w3.org/1999/xlink">1PP2</bold>
###xml 686 688 686 688 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 693 717 693 717 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Vipera russelli russelli</italic>
###xml 718 720 718 720 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B52">52</xref>
###xml 727 731 727 731 <bold xmlns:xlink="http://www.w3.org/1999/xlink">1VIP</bold>
###xml 737 741 737 741 <italic xmlns:xlink="http://www.w3.org/1999/xlink">bAhp</italic>
###xml 756 758 756 758 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 763 788 763 788 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Agkistrodon halys pallas </italic>
###xml 789 792 789 792 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B100">100</xref>
###xml 799 803 799 803 <bold xmlns:xlink="http://www.w3.org/1999/xlink">1JIA</bold>
###xml 456 480 <span type="species:ncbi:8714">Agkistrodon halys pallas</span>
###xml 523 548 <span type="species:ncbi:97228">Daboia russelli pulchella</span>
###xml 601 615 <span type="species:ncbi:8722">Bothrops asper</span>
###xml 648 662 <span type="species:ncbi:8730">Crotalus atrox</span>
###xml 693 717 <span type="species:ncbi:31159">Vipera russelli russelli</span>
###xml 763 787 <span type="species:ncbi:8714">Agkistrodon halys pallas</span>
Given the high sequence homology between the SVPLA2s and diverse PLA2s whose crystal structures are available, we applied homology modeling to generate 3D model structures of the SVPLA2s using the Biopolymer and Homology modules of the insightII software package (Accelrys Inc. San Diego, CA, USA). We retrieved the PLA2s of the template proteins of known 3D structure from the Protein Data Bank[95]. The template proteins are: AGTX, the neutral PLA2 from Agkistrodon halys pallas[96] (PDB 1A2A); VRV-PLVIII, the PLA2 from Daboia russelli pulchella[97] (PDB 1FB2); MtxII, myotoxin II, a K49-PLA2 from Bothrops asper. [98] (PDB 1CLP); the PLA2 from Crotalus atrox[99] (PDB 1PP2); the PLA2 from Vipera russelli russelli[52] (PDB 1VIP) and bAhp, the basic PLA2 from Agkistrodon halys pallas [100] (PDB 1JIA).
###end p 93
###begin p 94
###xml 463 466 463 466 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+ </sup>
###xml 479 482 479 482 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+ </sup>
###xml 1349 1355 1349 1355 <italic xmlns:xlink="http://www.w3.org/1999/xlink">et al.</italic>
###xml 1356 1358 1356 1358 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
After building the structurally conserved regions (SCR) and the structurally variable regions (SVR), we replaced the side chains of the template protein by the target protein's side chains in a predetermined library conformation. We then performed a rotamer search assignment in order to avoid atomic steric clashes and optimize the inter-residue energies. We included a structurally conserved catalytic water molecule during the modeling. We did not model the Ca2+ ion at the Ca2+ binding site, since it is absent in several X-ray structures. We subjected the obtained models to an overall internal energy minimization using the CFF91 force field. The protonation state of ionizable side chains and of the N- and C-termini was set for pH 7. Atomic partial charges were those of the CFF91 field. We used a distance-dependent dielectric function of 4r. We applied the cell multipole summation method for van der Waals and coulomb interactions. We used none of the cross terms of the force field. We applied the same conditions to the amino acid residues in the crystal structures used. We checked the stereo chemical quality of the models with the Struct_Check program, and the correctness of the folding with the Profiles3D Verify functionality (self-compatibility scores, insightII). The amino acid residue numbering is based on that of Renetseder et al.[15].
###end p 94
###begin title 95
Molecular Electrostatic Potential
###end title 95
###begin p 96
The MEP is generated by the combined presence of all partial charges residing on the atoms as a function of their positions. The potential was calculated with the DelPhi 2.5 program in insightII. The grid resolution was of 0.833 A/grid point. The interior and exterior dielectric constants were 2 and 80, respectively. The value of the ionic strength was 0.145; the probe radius was 1.4 A and the ionic radius 2.00 A. The treatment of the grid points at the boundary used a full Coulomb approximation. The values of the potential are given in kT/e units at T = 298 K.
###end p 96
###begin title 97
Molecular docking. Protein interfaces and interface contacts
###end title 97
###begin p 98
###xml 95 98 95 98 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B101">101</xref>
###xml 505 514 505 514 <italic xmlns:xlink="http://www.w3.org/1999/xlink">a priori </italic>
###xml 676 677 676 677 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
We generated the molecular complexes with the PatchDock rigid body molecular docking procedure[101]. Given two molecules, the surfaces of the molecules to dock are divided by PatchDock into patches according to the surface shape. These patches correspond to patterns that visually distinguish between puzzle pieces. We used a clustering RMSD criterion of 4.0 A. The output lists the rank of the complex and its approximate interface area. We selected PatchDock for the docking simulations since it allows a priori focusing on the vicinity of potential binding sites. In other words, it is possible to upload a receptor-binding site and a ligand-binding site. We took the SVPLA2s as the "receptor" molecules and FXa as the "ligand" molecule.
###end p 98
###begin p 99
###xml 59 60 59 60 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 181 183 181 183 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 283 285 283 285 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B39">39</xref>
###xml 628 630 625 627 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B39">39</xref>
Thus, we generated molecular complexes only for those SVPLA2s for which we find experimental evidence of biophysical interaction, i.e., in which the binding affinity between the PLA2 and FXa, as measured by SPR, was high. In addition, we used the available mutagenesis data for AtxA[39] to filter the docked complexes so that AtxA residues that show a decrease in the binding affinity for FXa are at the interface of the complex and define a binding site. The residues defining the binding site on AtxA are Arg72, Lys74, His76 and Arg77 (front edge of the beta-wing), and Arg118, Lys127, Lys128 and Lys132 (C-terminal fragment)[39]. We defined no ligand-binding site for FXa.
###end p 99
###begin p 100
###xml 240 242 237 239 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 331 332 328 329 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 758 761 751 754 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B102">102</xref>
###xml 891 894 884 887 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2+ </sup>
From the candidate complexes generated by PatchDock for AtxA, only one showed a binding mode compatible with the ensemble of the mutagenesis data -many complexes showed binding to either the beta-wing or the C-terminal fragment of the SVPLA2 or other regions of the AtxA. Thereafter, we selected those complexes for the other SVPLA2s that showed the same binding mode as AtxA and whose Calpha RMSDs with respect to the AtxA-FXa complex were minimal. After generation of the complexes, we used the "move apart" option of PatchDock, which separates (by 1.6 A) the receptor and ligand subunits in order to eliminate steric hindrances at the interface. We further improved the fitting of the complex by applying firstly the SCWRL3 side chain modeling procedure [102], in which we froze all disulfide bonds, as well as the side chains of heavy chain residues Asp70 and Glu80, which chelate the Ca2+ ion in FXa. After the rotamer search, we applied additional energy minimizations in order to reach a minimal internal energy conformation. The entire approach assumes that no drastic conformational changes occur during complexation.
###end p 100
###begin p 101
###xml 39 41 39 41 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 111 113 111 113 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 114 117 114 117 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B103">103</xref>
On another hand, we submitted the SVPLA2 models to the Protein-Protein Interface Prediction (PPI-Pred) server [26,103] to predict their binding sites. PPI-Pred predicts protein-protein binding sites using a combination of surface patch analysis and a support vector machine trained on 180 proteins involved in both obligate and non-obligate interactions.
###end p 101
###begin p 102
###xml 159 162 159 162 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B104">104</xref>
###xml 163 166 163 166 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B105">105</xref>
###xml 358 361 358 361 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B106">106</xref>
###xml 362 365 362 365 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B107">107</xref>
###xml 459 460 459 460 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
The interface between the two polypeptide chains of each of the complexes was characterized with the Protein interfaces, surfaces and assemblies service PISA [104,105]. The interface contacts were obtained through a contact map analysis and characterized with the SPACE bioinformatics tools CMA (Contact Map Analysis) and CSU (Contacts of Structural Units) [106,107]. We show only interface contacts for which the contact area is equal to or greater than 10 A2.
###end p 102
###begin title 103
Abbreviations
###end title 103
###begin p 104
###xml 50 52 50 52 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 57 82 57 82 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Agkistrodon halys pallas </italic>
###xml 57 81 <span type="species:ncbi:8714">Agkistrodon halys pallas</span>
AGTX: agkistrodotoxin, the neurotoxic, neutral PLA2 from Agkistrodon halys pallas venom
###end p 104
###begin p 105
###xml 0 4 0 4 <italic xmlns:xlink="http://www.w3.org/1999/xlink">bAhp</italic>
###xml 19 21 19 21 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 26 36 26 36 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Gloydious </italic>
###xml 37 63 37 63 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Agkistrodon) halys pallas </italic>
bAhp: the basic PLA2 from Gloydious (Agkistrodon) halys pallas venom
###end p 105
###begin p 106
###xml 36 63 36 63 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Vipera ammodytes ammodytes </italic>
###xml 36 62 <span type="species:ncbi:8705">Vipera ammodytes ammodytes</span>
AtxA: isoform A of ammodytoxin from Vipera ammodytes ammodytes venom
###end p 106
###begin p 107
###xml 2 3 2 3 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
CA2: one of the isoforms of the acidic subunit of crotoxin
###end p 107
###begin p 108
###xml 3 4 3 4 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
CBa2, CBc: isoforms of the basic subunit of crotoxin
###end p 108
###begin p 109
###xml 74 96 70 92 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pseudocerastes fieldi </italic>
###xml 74 95 <span type="species:ncbi:47769">Pseudocerastes fieldi</span>
CbI: the alpha isoform of the acidic subunit of the CbI-CbII complex from Pseudocerastes fieldi venom
###end p 109
###begin p 110
###xml 53 75 53 75 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pseudocerastes fieldi </italic>
###xml 53 74 <span type="species:ncbi:47769">Pseudocerastes fieldi</span>
CbII: the basic subunit of the CbI-CbII complex from Pseudocerastes fieldi venom
###end p 110
###begin p 111
###xml 36 65 33 62 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Crotalus durissus terrificus </italic>
###xml 36 64 <span type="species:ncbi:8732">Crotalus durissus terrificus</span>
CTX: crotoxin, beta-neurotoxin from Crotalus durissus terrificus venom, made of acidic CA and basic CB subunits
###end p 111
###begin p 112
###xml 31 54 28 51 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pseudocerastes fieldii </italic>
CbI-CbII: beta-neurotoxin from Pseudocerastes fieldii venom, composed of CbI and CbII subunits
###end p 112
###begin p 113
###xml 15 20 <span type="species:ncbi:9606">human</span>
FVa: Activated human coagulation factor V
###end p 113
###begin p 114
###xml 15 20 <span type="species:ncbi:9606">human</span>
FXa: Activated human coagulation factor X, also known as Stuart factor or Stuart-Prower factor
###end p 114
###begin p 115
###xml 5 6 5 6 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 63 64 63 64 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 32 37 <span type="species:ncbi:9606">human</span>
hsPLA2: Non-pancreatic secreted human group IIA phospholipase A2
###end p 115
###begin p 116
IBS: Interfacial Binding Site
###end p 116
###begin p 117
###xml 2 4 2 4 <sub xmlns:xlink="http://www.w3.org/1999/xlink">on</sub>
<kon>: average association rate constant
###end p 117
###begin p 118
###xml 2 5 2 5 <sub xmlns:xlink="http://www.w3.org/1999/xlink">off</sub>
<koff:>: average dissociation rate constant
###end p 118
###begin p 119
###xml 2 4 2 4 <sub xmlns:xlink="http://www.w3.org/1999/xlink">d </sub>
###xml 4 7 4 7 <sup xmlns:xlink="http://www.w3.org/1999/xlink">app</sup>
###xml 53 56 53 56 <sub xmlns:xlink="http://www.w3.org/1999/xlink">off</sub>
###xml 60 62 60 62 <sub xmlns:xlink="http://www.w3.org/1999/xlink">on</sub>
<Kd app>: average apparent dissociation constant = <koff>/<kon>
###end p 119
###begin p 120
###xml 24 39 24 39 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Bothrops asper </italic>
###xml 24 38 <span type="species:ncbi:8722">Bothrops asper</span>
MtxII: Myotoxin II from Bothrops asper venom
###end p 120
###begin p 121
PL: Phospholipids
###end p 121
###begin p 122
###xml 0 3 0 3 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Vbb</italic>
###xml 12 14 12 14 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 19 38 19 38 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Vipera berus berus </italic>
###xml 19 37 <span type="species:ncbi:31156">Vipera berus berus</span>
Vbb: the PLA2 from Vipera berus berus venom
###end p 122
###begin p 123
###xml 0 4 0 4 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Catx</italic>
###xml 13 15 13 15 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 20 35 20 35 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Crotalus atrox </italic>
###xml 20 34 <span type="species:ncbi:8730">Crotalus atrox</span>
Catx: the PLA2 from Crotalus atrox venom
###end p 123
###begin p 124
RU: Resonance units
###end p 124
###begin p 125
###xml 4 5 4 5 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 31 32 31 32 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
sPLA2: Secreted phospholipase A2
###end p 125
###begin p 126
SPR: Surface plasmon resonance
###end p 126
###begin p 127
###xml 5 6 5 6 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 54 55 54 55 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
SVPLA2: Group IIA snake venom secreted phospholipase A2
###end p 127
###begin p 128
###xml 18 20 18 20 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 25 51 25 51 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Daboia russelli pulchella </italic>
###xml 25 50 <span type="species:ncbi:97228">Daboia russelli pulchella</span>
VRV-PLVIII the PLA2 from Daboia russelli pulchella venom
###end p 128
###begin title 129
Authors' contributions
###end title 129
###begin p 130
###xml 257 258 257 258 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 296 298 296 298 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
GF and RCM conceived the study, analyzed the results and wrote the manuscript. All authors performed the research. In particular, GF carried out SPR affinity measurements, prothrombinase inhibition experiments, and purification and carboxymethylation of PLA2s; VTG assisted in purification of PLA2 and participated in SPR studies and discussions; RCM carried out sequence analysis, molecular modeling and docking simulations.
###end p 130
###begin title 131
Acknowledgements
###end title 131
###begin p 132
This work was carried out in part in the Unite des Venins (Institut Pasteur), directed by Dr. Cassian Bon. We sincerely thank Dr. Graham Bentley for critical reading of the manuscript.
###end p 132
###begin article-title 133
Biochemical and molecular aspects of the coagulation cascade
###end article-title 133
###begin article-title 134
###xml 54 59 <span type="species:ncbi:9606">human</span>
Interaction of calcium with native and decarboxylated human factor X. Effect of proteolysis in the autolysis loop on catalytic efficiency and factor Va binding
###end article-title 134
###begin article-title 135
Comparative modeling methods: application to the family of the mammalian serine proteases
###end article-title 135
###begin article-title 136
Structural basis of substrate specificity in the serine proteases
###end article-title 136
###begin article-title 137
Evolutionary divergence of substrate specificity within the chymotrypsin-like serine protease fold
###end article-title 137
###begin article-title 138
Snake venom serine proteinases: sequence homology vs. substrate specificity, a paradox to be solved
###end article-title 138
###begin article-title 139
The regulation of clotting factors
###end article-title 139
###begin article-title 140
###xml 20 26 <span type="species:ncbi:9913">bovine</span>
The contribution of bovine Factor V and Factor Va to the activity of prothrombinase
###end article-title 140
###begin article-title 141
Interfacial enzymology: the secreted phospholipase A(2)-paradigm
###end article-title 141
###begin article-title 142
###xml 143 176 <span type="species:ncbi:8716">Agkistrodon piscivorus piscivorus</span>
Structural aspects of interfacial adsorption. A crystallographic and site-directed mutagenesis study of the phospholipase A2 from the venom of Agkistrodon piscivorus piscivorus
###end article-title 142
###begin article-title 143
###xml 10 15 <span type="species:ncbi:9606">human</span>
Action of human group IIa secreted phospholipase A2 on cell membranes. Vesicle but not heparinoid binding determines rate of fatty acid release by exogenously added enzyme
###end article-title 143
###begin article-title 144
Docking phospholipase A2 on membranes using electrostatic potential-modulated spin relaxation magnetic resonance
###end article-title 144
###begin article-title 145
###xml 27 32 <span type="species:ncbi:9606">human</span>
Unusual mode of binding of human group IIA secreted phospholipase A2 to anionic interfaces as studied by continuous wave and time domain electron paramagnetic resonance spectroscopy
###end article-title 145
###begin article-title 146
###xml 43 48 <span type="species:ncbi:9606">human</span>
Mapping the interfacial binding surface of human secretory group IIa phospholipase A2
###end article-title 146
###begin article-title 147
###xml 64 70 <span type="species:ncbi:9913">bovine</span>
###xml 84 98 <span type="species:ncbi:8730">Crotalus atrox</span>
A comparison of the crystal structures of phospholipase A2 from bovine pancreas and Crotalus atrox venom
###end article-title 147
###begin article-title 148
Receptors for a growing family of secreted phospholipases A2
###end article-title 148
###begin article-title 149
Neuronal receptors for phospholipases A(2)and beta-neurotoxicity
###end article-title 149
###begin article-title 150
Functional association of type IIA secretory phospholipase A(2) with the glycosylphosphatidylinositol-anchored heparan sulfate proteoglycan in the cyclooxygenase-2-mediated delayed prostanoid-biosynthetic pathway
###end article-title 150
###begin article-title 151
###xml 83 88 <span type="species:ncbi:9606">human</span>
Molecular basis for the association of group IIA phospholipase A(2) and decorin in human atherosclerotic lesions
###end article-title 151
###begin article-title 152
###xml 61 66 <span type="species:ncbi:9606">human</span>
Identification of an autoantigen on the surface of apoptotic human T cells as a new protein interacting with inflammatory group IIA phospholipase A2
###end article-title 152
###begin article-title 153
Natural inhibitors of toxic phospholipases A(2)
###end article-title 153
###begin article-title 154
Structure-function relationships and mechanism of anticoagulant phospholipase A2 enzymes from snake venoms
###end article-title 154
###begin article-title 155
Different protein targets for snake venom phospholipases A2
###end article-title 155
###begin article-title 156
###xml 82 100 <span type="species:ncbi:8665">Ophiophagus hannah</span>
Role of enzymatic activity in the antiplatelet effects of a phospholipase A2 from Ophiophagus hannah snake venom
###end article-title 156
###begin article-title 157
Excitement ahead: structure, function and mechanism of snake venom phospholipase A2 enzymes
###end article-title 157
###begin article-title 158
Improved prediction of protein-protein binding sites using a support vector machines approach
###end article-title 158
###begin article-title 159
###xml 0 5 <span type="species:ncbi:9606">Human</span>
###xml 107 112 <span type="species:ncbi:9606">human</span>
Human recombinant non pancreatic secreted platelet phospholipase A2 has anticoagulant activity in vitro on human plasma
###end article-title 159
###begin article-title 160
Determinants of the inhibitory action of purified 14-kDa phospholipases A2 on cell-free prothrombinase complex
###end article-title 160
###begin article-title 161
###xml 66 78 <span type="species:ncbi:31155">Vipera berus</span>
A phospholipase A2 with anticoagulant activity. I. Isolation from Vipera berus venom and properties
###end article-title 161
###begin article-title 162
A phospholipase A2 with anticoagulant activity. II. Inhibition of the phospholiped activity in coagulation
###end article-title 162
###begin article-title 163
###xml 32 48 <span type="species:ncbi:8654">Naja nigricollis</span>
The basic phospholipase A2 from Naja nigricollis venom inhibits the prothrombinase complex by a novel nonenzymatic mechanism
###end article-title 163
###begin article-title 164
Structure-function relationships of phospholipases. The anticoagulant region of phospholipases A2
###end article-title 164
###begin article-title 165
###xml 86 102 <span type="species:ncbi:8654">Naja nigricollis</span>
Targeting of venom phospholipases: the strongly anticoagulant phospholipase A(2) from Naja nigricollis venom binds to coagulation factor Xa to inhibit the prothrombinase complex
###end article-title 165
###begin article-title 166
###xml 114 130 <span type="species:ncbi:8654">Naja nigricollis</span>
The inhibition of clotting complexes of the extrinsic coagulation cascade by the phospholipase A2 isoenzymes from Naja nigricollis venom
###end article-title 166
###begin article-title 167
###xml 73 89 <span type="species:ncbi:8707">Vipera russellii</span>
Biphasic effect on platelet aggregation by phospholipase a purified from Vipera russellii snake venom
###end article-title 167
###begin article-title 168
Effect of Russell's viper venom phospholipase A on blood coagulation and platelet aggregation
###end article-title 168
###begin article-title 169
###xml 90 116 <span type="species:ncbi:8705">Vipera ammodytes ammodytes</span>
The C-terminal and beta-wing regions of ammodytoxin A, a neurotoxic phospholipase A2 from Vipera ammodytes ammodytes, are critical for binding to factor Xa and for anticoagulant effect
###end article-title 169
###begin article-title 170
What can venom phospholipases A(2) tell us about the functional diversity of mammalian secreted phospholipases A(2)?
###end article-title 170
###begin article-title 171
###xml 38 39 38 39 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 64 83 64 83 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Crotalus adamanteus</italic>
###xml 125 126 125 126 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 64 83 <span type="species:ncbi:8729">Crotalus adamanteus</span>
Amino acid sequence of phospholipase A2-alpha from the venom of Crotalus adamanteus. A new classification of phospholipases A2 based upon structural determinants.
###end article-title 171
###begin article-title 172
###xml 103 108 <span type="species:ncbi:9606">human</span>
Evolutionary relationships and implications for the regulation of phospholipase A2 from snake venom to human secreted forms
###end article-title 172
###begin article-title 173
###xml 113 129 <span type="species:ncbi:8654">Naja nigricollis</span>
The role of enzymatic activity in inhibition of the extrinsic tenase complex by phospholipase A2 isoenzymes from Naja nigricollis venom
###end article-title 173
###begin article-title 174
Correlation of enzymatic activity and anticoagulant properties of phospholipase A2
###end article-title 174
###begin article-title 175
###xml 126 143 <span type="species:ncbi:8714">Agkistrodon halys</span>
Expression, purification and biochemical characterization of a recombinant phospholipase A2, with anticoagulant activity from Agkistrodon halys Pallas
###end article-title 175
###begin article-title 176
###xml 159 179 <span type="species:ncbi:8726">Bothrops jararacussu</span>
Myotoxic phospholipases A(2) in bothrops snake venoms: effect of chemical modifications on the enzymatic and pharmacological properties of bothropstoxins from Bothrops jararacussu
###end article-title 176
###begin article-title 177
###xml 71 98 <span type="species:ncbi:103944">Trimeresurus mucrosquamatus</span>
###xml 109 113 <span type="species:ncbi:88087">habu</span>
Mechanism of the anticoagulant action of phospholipase A purified from Trimeresurus mucrosquamatus (Formosan habu) snake venom
###end article-title 177
###begin article-title 178
Snake venom phospholipases A2. A fluorescence study of their binding to phospholipid vesicles correlation with their anticoagulant activities
###end article-title 178
###begin article-title 179
###xml 97 112 <span type="species:ncbi:8707">Vipera russelli</span>
Dissociation of enzymatic activity from toxic properties of the most basic phospholipase A2 from Vipera russelli snake venom by guanidination of lysine residues
###end article-title 179
###begin article-title 180
###xml 32 37 <span type="species:ncbi:9606">human</span>
Inhibition of prothrombinase by human secretory phospholipase A2 involves binding to factor Xa
###end article-title 180
###begin article-title 181
###xml 18 23 <span type="species:ncbi:9606">human</span>
Basic residues of human group IIA phospholipase A2 are important for binding to factor Xa and prothrombinase inhibition comparison with other mammalian secreted phospholipases A2
###end article-title 181
###begin article-title 182
The three-dimensional structures of two toxins from snake venom throw light on the anticoagulant and neurotoxic sites of phospholipase A2
###end article-title 182
###begin article-title 183
###xml 92 110 <span type="species:ncbi:132961">Bungarus caeruleus</span>
Sequence and crystal structure determination of a basic phospholipase A2 from common krait (Bungarus caeruleus) at 2.4 A resolution: identification and characterization of its pharmacological sites
###end article-title 183
###begin article-title 184
Anticoagulant proteins from snake venoms: structure, function and mechanism
###end article-title 184
###begin article-title 185
###xml 65 93 <span type="species:ncbi:8732">Crotalus durissus terrificus</span>
The origin of the diversity of crotoxin isoforms in the venom of Crotalus durissus terrificus
###end article-title 185
###begin article-title 186
###xml 90 118 <span type="species:ncbi:8732">Crotalus durissus terrificus</span>
Multiplicity of acidic subunit isoforms of crotoxin, the phospholipase A2 neurotoxin from Crotalus durissus terrificus venom, results from posttranslational modifications
###end article-title 186
###begin article-title 187
###xml 79 91 <span type="species:ncbi:8693">horned viper</span>
###xml 93 114 <span type="species:ncbi:47769">Pseudocerastes fieldi</span>
Amino acid sequences of a heterodimeric neurotoxin from the venom of the false horned viper (Pseudocerastes fieldi)
###end article-title 187
###begin article-title 188
###xml 53 79 <span type="species:ncbi:8705">Vipera ammodytes ammodytes</span>
Ammodytoxin A, a highly lethal phospholipase A2 from Vipera ammodytes ammodytes venom
###end article-title 188
###begin article-title 189
###xml 121 133 <span type="species:ncbi:31156">common viper</span>
###xml 135 153 <span type="species:ncbi:31156">Vipera berus berus</span>
Isolation, partial characterization and complete amino acid sequence of the toxic phospholipase A2 from the venom of the common viper, Vipera berus berus
###end article-title 189
###begin article-title 190
###xml 121 135 <span type="species:ncbi:8725">Bothrops atrox</span>
Structural and functional characterization of myotoxin I, a Lys49 phospholipase A2 homologue from the venom of the snake Bothrops atrox
###end article-title 190
###begin article-title 191
###xml 17 31 <span type="species:ncbi:8722">Bothrops asper</span>
###xml 33 43 <span type="species:ncbi:8722">Terciopelo</span>
Myotoxin II from Bothrops asper (Terciopelo) venom is a lysine-49 phospholipase A2
###end article-title 191
###begin article-title 192
###xml 96 111 <span type="species:ncbi:8707">Vipera russelli</span>
Primary sequence determination of the most basic myonecrotic phospholipase A2 from the venom of Vipera russelli
###end article-title 192
###begin article-title 193
###xml 33 50 <span type="species:ncbi:8714">Agkistrodon halys</span>
Cloning of the BPLA(2) Gene from Agkistrodon halys Pallas
###end article-title 193
###begin article-title 194
###xml 84 101 <span type="species:ncbi:8714">Agkistrodon halys</span>
Amino acid sequence of a presynaptic neurotoxin, agkistrodotoxin, from the venom of Agkistrodon halys Pallas
###end article-title 194
###begin article-title 195
###xml 0 14 <span type="species:ncbi:8730">Crotalus atrox</span>
Crotalus atrox phospholipase A2. Amino acid sequence and studies on the function of the NH2-terminal region
###end article-title 195
###begin article-title 196
###xml 30 35 <span type="species:ncbi:9606">human</span>
Structure and properties of a human non-pancreatic phospholipase A2
###end article-title 196
###begin article-title 197
###xml 49 75 <span type="species:ncbi:8732">South American rattlesnake</span>
###xml 76 104 <span type="species:ncbi:8732">Crotalus durissus terrificus</span>
Crotoxin, a phospholipase A2 neurotoxin from the South American rattlesnake Crotalus durissus terrificus: purification of several isoforms and comparison of their molecular structure and of their biological activities
###end article-title 197
###begin article-title 198
Comparison of crotoxin isoforms reveals that stability of the complex plays a major role in its pharmacological action
###end article-title 198
###begin article-title 199
SPR study to characterize the snake venom phospholipases A2 mechanism of action
###end article-title 199
###begin article-title 200
A monoclonal antibody directed against the non-toxic subunit of a dimeric phospholipase A2 neurotoxin, crotoxin, neutralizes its toxicity
###end article-title 200
###begin article-title 201
Inhibition of crotoxin phospholipase A(2) activity by manoalide associated with inactivation of crotoxin toxicity and dissociation of the heterodimeric neurotoxic complex
###end article-title 201
###begin article-title 202
Studies of protein-protein interfaces: a statistical analysis of the hydrophobic effect
###end article-title 202
###begin article-title 203
Automated analysis of interatomic contacts in proteins
###end article-title 203
###begin article-title 204
###xml 38 53 <span type="species:ncbi:8707">Vipera russelli</span>
Antibodies to a phospholipase A2 from Vipera russelli selectively neutralize venom neurotoxicity
###end article-title 204
###begin article-title 205
###xml 41 58 <span type="species:ncbi:8714">Agkistrodon halys</span>
Structure of basic phospholipase A2 from Agkistrodon halys Pallas: implications for its association, hemolytic and anticoagulant activities
###end article-title 205
###begin article-title 206
###xml 102 126 <span type="species:ncbi:8714">Agkistrodon halys pallas</span>
Functionally important residues for the anticoagulant activity of a basic phospholipase A(2) from the Agkistrodon halys pallas
###end article-title 206
###begin article-title 207
The electrostatic basis for the interfacial binding of secretory phospholipases A2
###end article-title 207
###begin article-title 208
Molecular recognition sites on factor Xa which participate in the prothrombinase complex
###end article-title 208
###begin article-title 209
Identification of basic residues in the heparin-binding exosite of factor Xa critical for heparin and factor Va binding
###end article-title 209
###begin article-title 210
Substitution of asparagine for arginine 347 of recombinant factor Xa markedly reduces factor Va binding
###end article-title 210
###begin article-title 211
Definition of a factor Va binding site in factor Xa
###end article-title 211
###begin article-title 212
The critical role of the 185-189-loop in the factor Xa interaction with Na+ and factor Va in the prothrombinase complex
###end article-title 212
###begin article-title 213
###xml 40 45 <span type="species:ncbi:9606">human</span>
Identification of distinct sequences in human blood coagulation factor Xa and prothrombin essential for substrate and cofactor recognition in the prothrombinase complex
###end article-title 213
###begin article-title 214
###xml 156 161 <span type="species:ncbi:9606">human</span>
###xml 266 285 <span type="species:ncbi:29170">Ancylostoma caninum</span>
Intermolecular interactions and characterization of the novel factor Xa exosite involved in macromolecular recognition and inhibition: crystal structure of human Gla-domainless factor Xa complexed with the anticoagulant protein NAPc2 from the hematophagous nematode Ancylostoma caninum
###end article-title 214
###begin article-title 215
###xml 34 39 <span type="species:ncbi:9606">Human</span>
###xml 146 165 <span type="species:ncbi:29170">Ancylostoma caninum</span>
Active and Exo-site Inhibition of Human Factor Xa: Structure of des-Gla Factor Xa Inhibited by NAP5, a Potent Nematode Anticoagulant Protein from Ancylostoma caninum
###end article-title 215
###begin article-title 216
Detection, using antibodies, of pharmacologically active sites, apart from the catalytic site, on venom phospholipase A2
###end article-title 216
###begin article-title 217
Charge reversal of ammodytoxin A, a phospholipase A2-toxin, does not abolish its neurotoxicity
###end article-title 217
###begin article-title 218
###xml 41 62 <span type="species:ncbi:47769">Pseudocerastes fieldi</span>
The neurotoxic complex from the venom of Pseudocerastes fieldi. Contribution of the nontoxic subunit
###end article-title 218
###begin article-title 219
###xml 32 37 <span type="species:ncbi:9606">human</span>
The anticoagulant effect of the human secretory phospholipase A2 on blood plasma and on a cell-free system is due to a phospholipid-independent mechanism of action involving the inhibition of factor Va
###end article-title 219
###begin article-title 220
Probing the subpockets of factor Xa reveals two binding modes for inhibitors based on a 2-carboxyindole scaffold: a study combining structure-activity relationship and X-ray crystallography
###end article-title 220
###begin article-title 221
Rapid and sensitive protein similarity searches
###end article-title 221
###begin article-title 222
Improved tools for biological sequence comparison
###end article-title 222
###begin article-title 223
Weblogo
###end article-title 223
###begin article-title 224
WebLogo: a sequence logo generator
###end article-title 224
###begin article-title 225
The Protein Data Bank
###end article-title 225
###begin article-title 226
###xml 90 114 <span type="species:ncbi:8714">agkistrodon halys pallas</span>
Crystal structure of agkistrodotoxin, a phospholipase A2-type presynaptic neurotoxin from agkistrodon halys pallas
###end article-title 226
###begin article-title 227
###xml 94 119 <span type="species:ncbi:97228">Daboia russelli pulchella</span>
Regulation of catalytic function by molecular association: structure of phospholipase A2 from Daboia russelli pulchella (DPLA2) at 1.9 A resolution
###end article-title 227
###begin article-title 228
At the interface: crystal structures of phospholipases A2
###end article-title 228
###begin article-title 229
The refined crystal structure of dimeric phospholipase A2 at 2.5 A. Access to a shielded catalytic center
###end article-title 229
###begin article-title 230
###xml 43 60 <span type="species:ncbi:8714">Agkistrodon halys</span>
Structure of a basic phospholipase A2 from Agkistrodon halys Pallas at 2.13 A resolution
###end article-title 230
###begin article-title 231
Taking geometry to its edge: fast unbound rigid (and hinge-bent) docking
###end article-title 231
###begin article-title 232
A graph-theory algorithm for rapid protein side-chain prediction
###end article-title 232
###begin article-title 233
PPI-Pred
###end article-title 233
###begin article-title 234
PISA
###end article-title 234
###begin article-title 235
SPACE: a suite of tools for protein structure prediction and analysis based on complementarity and environment
###end article-title 235

